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Chapter1: Background 
 
1.1 Prostate cancer (PCa) 
1.1.1 Epidemiology 
Incidence, prevalence, and mortality 
PCa is the most frequent malignancy among Norwegian men (1). In 2002–2006, the annual 
number of new cases was 2766 to 3829 in a population of about 4.7 million, representing 27% 
of all new male cancers in that period. The Norwegian incidence rates/100 000 person-years 
(age adjusted to the world’s standard population) were 71.1 to 98.3 in the same period. PCa 
was responsible for 1074 deaths in 2004 (19% of all cancer deaths) and was the second-
leading cause of cancer deaths in men after lung cancer. By the end of 2006, 23 389 men with 
a prior diagnosis of PCa were alive. 
In a global perspective, the incidence of PCa has been increasing for many years, 
especially in industrialized countries including Norway. The incidence is particularly high in 
the USA and extremely low in China, giving updated age adjusted incidence rates/100 000 
person-years of 124.8 and 1.7 respectively (2). The true prevalence of the disease (the number 
of men with diagnosed or undiagnosed PCa in a certain population at a given time) assessed 
by autopsy studies shows less variation than does the incidence rate (2). Because a large 
proportion is clinically indolent tumors, the incidence rate depends strongly on efforts to 
detect tumors in men without symptoms. The observed increase in incidence before the 
prostate-specific antigen (PSA) era has been attributed to aging of the population in general 
and increased attention to prostate-related symptoms combined with surgical treatment of 
benign hyperplasia of the prostate (3). From around 1990, when assessment of PSA in serum 
became common in clinical practice, a steep increase was observed in many countries (3). 
Different attitudes towards PSA screening of asymptomatic men may partly explain 
geographical differences in incidence rates (3;4). In areas with liberal screening, like the USA, 
a stage migration has accompanied the increased incidence rates so that a higher proportion of 
diagnosed tumors are organ confined than before the PSA era (5).    
Mortality rates have increased constantly in many countries over the past 60 years but 
seem now to have reached a plateau or have declined slightly (1-4). Whether this trend can be 
explained by increased detection at an early stage with subsequent curative treatment is not 
clear (4). For unknown reasons, Scandinavian countries have the highest PCa-related 
mortality rates in the world (2).  
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Risk factors 
Age is the single most important risk factor. In Norway, nearly 90% of all new cases in 2006 
were diagnosed in men age 60 years or older (1). A recent autopsy study of men without a 
history of PCa during their lifetime documented an age-dependent increase of asymptomatic 
tumors, with positive findings in more than 60% of men aged more than 80 years (6). 
Diet is thought to play a role in both prevalence and incidence. A relatively low 
autopsy prevalence in Mediterranean countries (2) and higher incidence in first-generation 
immigrants to the USA from countries with low incidence (7) suggest that a diet rich in 
antioxidants based on cereals, vegetables and fish may  be protective compared with a diet 
rich in dairy products and red meat. This view is supported by data from clinical trials (8). 
Specific compounds that may be chemopreventive include phytoestrogens (9), lycopenes (10), 
and omega-3 fatty acids (11).   
Hereditary PCa is thought to explain 5–10% of all cases and is generally diagnosed six 
to seven years earlier than sporadic cases (12). Special interest has been directed towards 
inherited mutation of the tumor suppressor gene breast cancer type 2 susceptibility protein 
(BRCA2), which is associated with increased risk of PCa and seemingly with a particularly 
aggressive phenotype (13;14).  
 
1.1.2 Tumor classification and staging 
In this thesis, tumors are classified using the sixth version of the tumor–node–metastases 
(TNM) system (Table 1.1), published in 2002 (15). 
 
T staging 
Before treatment, the local extent of the tumor is usually assessed by digital rectal 
examination. Transrectal ultrasound is often used as a supplement, but is not more accurate 
than digital rectal examination for predicting extracapsular disease (16). Neither does 
conventional magnetic resonance imaging (MRI) or positron emission tomography accurately 
predict extracapsular extension (17;18). Advances in for example MRI-based imaging 
techniques (19) will hopefully provide more accurate T classification because digital rectal 
examination underestimates extracapsular growth in about 30% of cases (16). 
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Table 1.1 Clinical classification of adenocarcinoma of the prostate (15) 
T1 Clinically unapparent tumor not palpable or visible by imaging  
   T1a Tumor incidental histological finding in  5% of resected tissue 
   T1b Tumor incidental histological finding in > 5% of resected tissue 
   T1c Tumor detected by needle biopsy (e.g. because of elevated PSA) 
T2 Clinically apparent tumor confined within the prostate 
   T2a Tumor involves  half of one lobe 
   T2b Tumor involves > half of one lobe but not both lobes 
   T2c Tumor involves both lobes 
T3 Tumor penetrates the prostatic capsule 
   T3a Extracapsular extension 
   T3b Tumor invades the seminal vesicle(s)  
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles; bladder neck, external 
sphincter, rectum, levator muscles and/or pelvic wall 
N0 No regional lymph node metastases  
N1 Regional lymph node metastases 
Nx Regional lymph node status not assessed  
M0 No distant metastases 
M1 Distant metastases  
Histopathologically assessed TN classifications are referred to as pT and pN. Clinically assessed T classification 
is referred to as cT. 
 
 
N staging  
The gold standard for assessing regional lymph node involvement is pelvic lymphadenectomy 
combined with histopathological evaluation of the lymph nodes removed. The procedure is 
performed in patients who are candidates for curatively intended therapy. According to the 
European Association of Urology (EAU) guidelines (20), patients with T-category  2a and 
Gleason score (GS)  6 and PSA < 20μg/L may be spared lymphadenectomy because they 
have less than a10% risk of lymph node involvement according to a frequently used 
nomogram (21). There is ongoing controversy about the optimal extent of lymph node 
dissection: Anatomical and clinical studies have shown that extended dissection with removal 
of at least 20 pelvic lymph nodes is required for optimal staging (22;23). However, two small 
clinical trials concluded that such extended dissection has no benefit over a more limited 
dissection (24;25). On the other hand, extended lymph node dissection may remove occult 
disease as shown in studies based on  immunocytochemistry (ICC) and reverse transcriptase-
polymerase chain reaction (RT-PCR) (26;27). Computed tomography (CT) and MRI are 
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currently not suitable for excluding lymph node involvement because of poor sensitivity (28). 
MRI after administration of lymphotropic superparamagnetic nanoparticles may improve the 
sensitivity, but this method has not been implemented in clinical practice (29).  
 
M staging 
Distant metastases in PCa occur most frequently in bone followed by lung, liver, pleura, and 
adrenals in descending order (30). Technetium bone scan is recommended by the EAU for 
primary staging of bone metastases (20). Chest X-ray, ultrasound, CT, and MRI are useful if 
symptoms indicate soft tissue metastases. MRI may clarify inconclusive findings from the 
bone scan (31).  
 
1.1.3 Histopathological grading  
Histopathological grading according to Gleason was recommended by a World Health 
Organization (WHO) consensus conference in 1993 (32) and is now the predominant grading 
system for adenocarcinoma of the prostate. The pattern of glandular differentiation is graded 
from 1 to 5, regardless of nuclear atypia. The conventional GS is the sum of the dominant and 
secondary grade and is noted as “dominant grade + secondary grade = GS” without reference 
to high-grade tertiary components (high grade refers to patterns 4 and 5). However, tertiary 
components of grade 4 or 5 in prostatectomy specimens add important prognostic information 
(33). Consequently, after a recent consensus conference, it is recommended that needle biopsy 
specimens with grades 3,4 and 5 both the primary grade and the highest grade should be 
recorded so that tumors with conventional GS 3 + 4 = 7 and a tertiary grade 5 should be 
recorded as GS 3 + 5 = 8 (34). However, radical prostatectomy specimens should still be 
scored according to the conventional method along with a comment about the high-grade 
tertiary patterns. It is also recommended that a GS 2–4 in a needle biopsy specimen should not 
be reported because of substantial undergrading compared with the prostatectomy scores. 
 The “percentage of Gleason pattern 4/5” (i.e. the relative amount of the tumor that is 
of high grade) has been studied as an alternative or supplement to the GS (35). Further, 
assessment of the extent of tumor tissue in the needle biopsy specimen may give prognostic 
information independent of the GS (36). The tumor extent may be measured in several ways 
including the percentage of prostate needle biopsy cores with cancer (“percent positive 
biopsies”) and “percentage tumor length in all cores” (the total length of tumor tissue relative 
to the total length of cores).  
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According to a review by Humphrey of 3789 cases, the conventional GS was 
undergraded in needle biopsies compared with the whole gland in 42% of cases and 
overgraded in 15% (37). An exact correlation between needle biopsies and prostatectomy 
specimens was found in 43% of cases and agreement to within one score unit was found in 
77% of cases.  Although the GS is a robust prognostic factor, problems with inter- and intra 
observer variation remain to be solved (38).In clinical studies, GS is frequently categorized 
into three groups as GS < 7, GS = 7 or GS > 7. An alternative is dichotomization into GS  
7A (3 + 4) versus GS  7B (4 + 3) (39).  
The most common alternative grading system, called the WHO grading system, 
combines glandular differentiation (well differentiated, moderately differentiated, poorly 
differentiated or undifferentiated) and nuclear atypia (nuclear grades one to three) (40). At the 
Norwegian Radium Hospital (NRH), the GS replaced the WHO system as the standard 
grading system around 2000 (39). 
In prostatectomy specimens, histopathological assessment of pT-category and 
extension into surgical margins and/or seminal vesicles add prognostic information that is 
missing in patients who are treated by radiotherapy.   
 
1.1.4 Serum biomarkers   
PSA is currently one of the most important biomarkers in oncology. The glycoprotein is 
normally produced in the prostate gland and acts as an enzyme to catalyze the reaction that 
brakes down coagulated sperm (i.e. keeps the sperm fluid after ejaculation). Several 
conditions are associated with elevated serum-PSA concentration, including benign 
hyperplasia of the prostate, prostatitis, and PCa. PSA is used routinely for diagnosis and 
follow-up of PCa. Additionally, bone-specific markers such as the bone isoenzym of alkaline 
phosphatase reflect the extent of bone metastasis (41). Several other promising markers are 
under investigation for use in different clinical settings (42), although none is currently in 
routine clinical use, and they will not be discussed further.  
  
Diagnostic PSA assessment  
Opportunistic screening (i.e. patient- or doctor-initiated PSA testing) for early detection of 
PCa has led to a marked increase in the incidence of PCa in Western countries. The cost has 
been many unnecessary biopsies and diagnoses of irrelevant tumors, which would not produce 
clinical symptoms during the patients’ lifetime (overdiagnosis). Ongoing studies are 
investigating the cost–benefit of population-based screening programs (43;44). Important 
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problems related to PSA screening are the absence of a lower threshold that excludes 
clinically important cancers (Table 1.2) (45) and the low positive predictive value for positive 
prostate biopsies when PSA is < 10 μg/L (46).  
Use of PSA isoforms to determine the free-PSA/total PSA ratio or complex PSA can 
probably improve the cancer-related specificity of PSA (47). PSA kinetics based on repeated 
PSA determinations in the lower range might help select patients with clinically relevant 
tumors (48).   
 
                   Table 1.2. Prevalence of PCa diagnosed by biopsy in men with  
                    normal digital rectal examination and PSA  4 μg/L (45) 
 
PSA 
Prevalence of 
prostate cancer 
Fraction of cancers with 
Gleason Score  7 
 0.5 μg/L 6.6% 12.5% 
0.6–1.0 μg/L 10.1% 10.0% 
1.1–2.0 μg/L 17.0% 11.8% 
2.1–3.0 μg/L 23.9% 19.1% 
3.1–4.0 μg/L 26.9% 25.0% 
                                  Abbreviations: PSA; prostate-specific antigen 
 
PSA during follow-up 
PSA is used widely to monitor disease activity during follow-up of PCa patients. PSA 
concentration usually decreases to an undetectable or low but stable level following successful 
curative local therapy. Clinical relapse without a preceding increase in PSA concentration is 
extremely rare (49), but may occur theoretically in poorly differentiated cancers that have lost 
their ability to produce PSA. In contrast, increasing PSA concentration most often reflects 
treatment failure (50) and may allow for early secondary intervention. One problem is that 
increasing PSA concentration does not reliably differentiate between loco regional 
progression and metastatic disease. Furthermore, patients with limited life expectancy may 
not benefit from an intervention based on increasing PSA concentration without clinical 
symptoms. PSA kinetics (i.e. PSA doubling time) has been shown to add prognostic 
information and may help to select patients with PSA recurrence who will benefit from 
intervention (51).  
Exact definitions of PSA recurrence following curatively intended local therapy are 
needed to achieve uniformity in clinical studies. The American Society for Therapeutic 
Radiology and Oncology (ASTRO) defined PSA recurrence following radiotherapy as three 
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consecutive increases in PSA concentration (the ASTRO definition) (52). A second consensus 
meeting in Phoenix 2005 held by ASTRO and the Radiation Therapy Oncology Group 
(RTOG) recommended that an increase in PSA concentration of 2 μg/L greater than the nadir 
value should be the standard definition of PSA recurrence following radiotherapy with or 
without adjuvant hormone therapy (HT) (called the Houston definition, the Phoenix 
definition, or the ASTRO/RTOG definition) (53). This definition has been shown to be a 
better predictor of subsequent clinical progression following radiotherapy than the former 
ASTRO definition (54). Following radical prostatectomy, two consecutive findings of PSA 
concentration of 0.2 μg/L or greater is a commonly used definition (55) that is recommended 
by the EAU (56). 
Longitudinal changes in PSA concentration are also valuable to consider in a palliative 
setting for the response evaluation of systemic therapies such as HT or chemotherapy.    
 
1.1.5 Natural history  
It is important to consider the expected prognosis in newly diagnosed PCa if left untreated 
when the type of treatment is to be decided. The reality of how different phenotypes behave 
through their life cycle will never be known completely because active treatment hampers the 
interpretation. Our current knowledge is based on studies of conservatively treated patients 
(i.e. patients without local treatment with curative intention). The following section discusses 
some of the studies that provided information about the natural history of PCa. 
 In the pre-PSA era, PCa was diagnosed mainly by of symptoms, the presence of 
palpable tumors, or incidental findings on specimens from transurethral resection because of 
prostate hyperplasia. These tumors represented a phenotypically more homogeneous group 
compared with T1c tumors, which are diagnosed mainly based on PSA measurements. 
Therefore, the natural history of localized PCa should be considered separately for tumors 
diagnosed before and after the introduction of PSA into routine clinical practice.         
 
Prognosis of conservatively managed localized PCa in the pre-PSA era 
Johanssen et al prospectively followed 223 patients with newly diagnosed cT1–2pNXM0 PCa 
whose treatment was delayed until progression (57). Ninety-six percent of the tumors were 
well or moderately differentiated. During a mean follow-up of 21 years, 36% of the tumors 
progressed locally and 17% of the patients developed distant metastases. Seventeen percent of 
the 203 patients who died during the observation period died because of PCa. The cumulative 
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20-year PCa-specific survival rate was 72% for patients with well-differentiated tumors and 
22% for patients with moderately differentiated tumors.   
Albertsen et al retrospectively studied 767 men treated by observation or immediate or 
delayed HT. Most of these men had cT1–2 tumors, but 5% had cT3 tumors and 24% had 
palpable tumors on digital rectal examination without further specification regarding capsule 
penetration. The absolute risk of dying because of PCa within a median of 24 years follow-up 
varied from 7% in low-grade tumors (GS 2–4) to 66% in high-grade tumors (GS 8–10).  
The clinical outcomes in the observation arm of the so far only randomized study that 
has shown a gain in PCa-specific survival following radical prostatectomy also provided 
useful information about the prognosis of untreated PCa. Three hundred forty-eight men with 
cT1–2NXM0 PCa were randomized to expectant managing and received no initial treatment 
except for transurethral resection of the prostate in 16% of cases (58). At 12 years follow-up, 
the cumulative overall mortality was 40%, the PCa-specific mortality was 18%, and the risk 
of distant metastases was 26%. The cumulative 10-year risk of local progression was 44% in 
an earlier report (59).     
Although many of the patients in these studies received treatment such as transurethral 
resection of the prostate or HT, the results provided evidence that localized low-grade tumors 
rarely kill patients and that patients with high-grade tumors have a high risk of dying because 
of cancer within 5–10 years of diagnoses if left untreated. The outcome in men with 
intermediate histological differentiation shows greater variation. 
 
Prognosis of conservatively treated T1c tumors 
The outcome from conservatively treated T1c tumors will not be known until the results from 
two ongoing randomized trials are compiled: The Prostate Cancer Intervention versus 
Observation Trial (PIVOT) have randomized American men for prostatectomy or expectant 
management (60). The Prostate Testing for Cancer and Treatment (ProtecT) trial randomized 
British PCa patients to active monitoring, definitive radiotherapy, or prostatectomy beginning 
in 2001 (61). Awaiting the results from these trials, Parker et al performed a modeling study 
to predict the natural history of PCa detected by screening (62). The results from the study by 
Albertsen et al (63) were adjusted for estimates of lead time (time difference between 
screening detection and clinical detection in the absence of screening), overdetection 
(diagnosis of tumors that would never have been diagnosed during the patient’s lifetime) (64), 
and overall reduction in mortality and survival benefits from early curative treatment (59). 
The projected 15-year cause-specific survival rates in men aged 55–59 years whose tumors 
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had a GS < 7, 7 and > 7 were 100%, 69%, and 29%, respectively. For men aged 70–74 years, 
the corresponding values were 98%, 91%, and 72%.  
  
Prognosis of conservatively managed locally advanced PCa (T3–4NXM0)   
Tumors that are locally advanced at diagnosis have a capacity for infiltrative growth and 
therefore represent a subpopulation of tumors with a more uniform phenotype than localized 
tumors. Extracapsular growth is associated with increased risk of regional lymph node 
metastases as shown by Bader et al (22). Performing extensive pelvic lymph node dissection, 
they found lymph node metastases in 0%, 13%, 22%, 52%, and 50% of patients with pT1, pT2, 
pT3a, pT3b, and pT4 tumors, respectively.  
Patients with locally advanced tumors are usually candidates for immediate treatment, 
and population-based observational studies of initially untreated patients have not been 
performed. However, one randomized study provided useful information about the 
aggressiveness of this group of tumors (65). In one arm, 244 men with NXM0 PCa considered 
too advanced for curative treatment were followed for 2.5 to 11 years. No initial treatment 
was given, and palliative HT was delayed until progression. The cumulative risk of distant 
metastases at five years was 58% (65). PCa was the cause of death in at least 60% of the 
patients who died within the observation period. The patients were not stratified by 
histopathological grading.  
 
Prognosis of conservatively managed locally advanced PCa with regional lymph node 
metastases (pN1M0)     
Schröder et al compared immediate HT versus delayed HT until progression in patients with 
regional lymph node metastases caused by PCa who had not received local treatment (66). 
The median follow-up was 8.7 years. Out of those who were randomized to delayed 
treatment, PCa was the cause of death in 76% who died during the observational period.   
 
1.1.6 The metastatic process 
Prior to dissemination, tumor cells have to acquire the abilities to shed and migrate from the 
primary tumor. Molecular changes which in part may explain such phenotypical shift may be 
referred to as the epithelial-mesenchymal transition because they to a certain degree imitate 
the development of mesenchymal cells during the embryogenesis (67). Development of 
distant metastases frequently occurs many years after curatively intended local therapy in 
patients without local relapse (58;68). Therefore, dissemination of tumor cells seems to be an 
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early event in cancer development, and these cells may remain dormant for many years before 
they form overt metastases (69). This view is supported by evidence of existing single tumor 
cells in peripheral blood, lymph nodes, and bone marrow (BM) in many PCa patients without 
clinically manifest metastases (26;70-76). The tumor cells isolated from blood or BM of M0 
patients seem to be genetically more heterogeneous than tumor cells isolated from patients 
with overt distant metastases (77;78). These findings suggest that genetic mutations, which 
may facilitate the formation of distant metastases, partly are acquired after the cells are shed 
from the primary tumor.  
As early as in 1940, Batson presented evidence of metastatic spread through the pelvic 
veins that connect the vasculature of the spine with that of pelvic structures (79), frequently 
referred to as Batson’s veins. He also suggested that an increase in intra-abdominal pressure 
facilitates venous flow from the prostate backward to the spine through these veins instead of 
forward to the vena cava. His findings were supported by later animal studies (80). A recent 
autopsy study also supported Batson’s theories (30). Hematogenously disseminated PCa 
lesions were found in 556 men, most frequently in bone (90%), lung (46%), liver (25%), 
pleura (21%) and adrenals (13%) (30). Of the men with bone metastases, 90% had lesions in 
the spine, most frequently in the lumbar region. Involvement of the thoracic or cervical spine 
without lesions in the lumbar spine was rare. Furthermore, an inverse relation was found 
between metastases to the lung and spine. In the same study, 84% of 415 men with pelvic or 
para-aortic lymph node metastases from PCa also had hematogenous metastases compared 
with only 16% in 996 men with PCa without lymph node involvement. Thus, a biologic link 
between lymphatic and hematogenous dissemination seems reasonable. 
The preference for disseminated PCa cells to form metastases in lymph nodes and BM 
may relate to several factors and is understood only partly (81). As early as in 1889, Paget 
introduced his “seed and soil” hypothesis (82). According to that theory, the interactions 
between tumor cells and the microenvironment at the distant site are crucial for whether 
metastases develop at that specific site. Findings from recent experimental studies support this 
view: Expression of chemoattractant molecules in bone and lymph nodes may direct prostate 
cell migration towards these organs (homing). Several possible chemoattractants with 
relevance to PCa have been identified (81). One is epidermal growth factor, which may direct 
PCa cells toward both lymph nodes and BM (83). The preferred adhesion of PCa cells to BM 
endothelium compared with other epithelia may facilitate the development of bone metastases 
(84). Furthermore, factors like insulin-like growth factor are produced by osteoblasts and 
stimulate the proliferation of PCa cells in vitro (85). PCa cells also affect bone homeostasis by 
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producing molecules that stimulate osteoblasts and osteoclasts, enhancing bone formation and 
bone degradation, respectively (86). Increased bone turnover may increase the release of 
growth factors that in turn stimulate cancer cell proliferation.      
 
1.1.7 Endocrine aspects 
In 1941, Charles Higgins (19011997) and his research fellow Clarence Hodges (1914–2001) 
documented that PCa activity is inhibited when serum androgen concentration is deprived 
(87). Interference with androgen receptor activity has been the mainstay in systemic treatment 
of PCa after this finding, for which Higgins received the Nobel Prize in 1966. We now know 
that activation of the androgen receptor is crucial for cell proliferation and tissue maintenance 
both in normal prostate tissue and PCa (88). Testosterone is taken up from the blood by 
prostate epithelia and converted to dihydrotestosterone through an enzymatic process driven 
by 5α-reductase. Dihydrotestosterone has strong affinity for the androgen receptor, which, 
subsequent to ligand binding, binds to DNA within regulatory regions of the target genes.  
 
Castration 
In men, about 95% of circulating androgens are synthesized from cholesterol in the gonadal 
Leydige cells (89). Nongonadal androgen production occurs mainly in the adrenals. Surgical 
castration leads to an immediate decrease in serum testosterone concentration and remains the 
gold standard in treatment of advanced symptomatic PCa. However, in clinical practice, 
castrate levels of testosterone are usually achieved pharmaceutically by interfering with the 
feedback mechanisms of the hypothalamic–pituitary–gonadal axis. The mainstay of such 
medical castration is currently gonadotropin releasing hormone (GnRH) agonists. 
Administration of such compounds initially stimulates and, a few days later, inhibits 
hypothalamic production of GnRH. The subsequent decrease in the production of pituitary 
luteinizing hormone (LH) hampers androgen production in the testis. Endocrine side effects of 
castration include erectile dysfunction and loss of libido, decreased bone density, decreased 
muscle mass, hot flashes and possibly psychological effects such as fatigue and impaired 
vitality (90;91). Furthermore, long-term use of GnRH agonists is associated with increased 
risk of diabetes and cardiovascular disorders (92). Estradiol is synthesized from testosterone 
and serum estradiol concentration is low in castrated men. This is probably the reason for 
castration-associated loss of bone mass. Earlier, medical castration was achieved by estradiol 
compounds without this disadvantage. However, such treatment was associated with higher 
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cardiovascular mortality compared with GnRH agonists and is therefore not currently 
recommended standard first-line treatment (93).  
Compared with radiotherapy alone for locally advanced or localized high-grade PCa, 
adjuvant castration-based therapy improves clinical outcomes (94-98).  
 
Androgen receptor blockade    
Androgen receptor activity may be blocked without interfering directly with androgen 
production using antiandrogen (AA) compounds that competitively inhibit the androgen 
receptors. In contrast to castration-based therapy, the gonadal androgen production is not 
inhibited by peroral nonsteroidal AAs. Instead, testosterone and estradiol concentration 
increases in the serum (99) probably because of androgen receptor blockade in the pituitary 
gland and hypothalamus, which inhibits the negative feedback regulation that normally occurs 
in response to high serum sex-hormone concentrations. Breast hypertrophy and breast pain 
(100) are frequently occurring adverse effects, probably related to the increased estradiol 
concentration. Bone mineral density seems to be maintained during AA treatment (101). 
Preservation of sexual function is by many clinicians considered a main advantage of AAs 
over GnRH agonists (102). In a randomized trial, sexual and physical function was better after 
one year of treatment with the AA bicalutamide compared with GnRH agonist (100). 
However, in another study, long-term treatment with flutamide was associated with a gradual 
loss of erectile function over the first few years of treatment (103). The side effects from AAs 
and GnRH agonists have not been compared in randomized studies with longer follow-up 
than two years (100;101). 
In locally advanced PCa, radiotherapy + AA has been shown to improve overall 
survival and PCA-specific survival compared with radiotherapy alone (104) and AA alone 
(105).  AA monotherapy is not recommended for localized PCa because a randomized trial 
showed a trend toward poorer overall survival during such treatment compared with watchful 
waiting (104).  
 
Castrate-resistant PCa  
In most cases, HT is only effective for a limited timeperiod. One mechanism behind tumor-
progression during HT is probably related to increasing number within the tumor of 
neuroendocrine cells without androgen receptors (106). In addition, recent data show that 
androgen receptor-mediated tumor progression is important, despite castrate levels of serum 
androgens (107). The term “castrate-resistant PCa” is therefore now preferred over the 
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previously used “hormone- or androgen independent PCa”. The concentration of intracellular 
androgens is higher in tissues from metastatic castrate-resistant PCa than in PCa that responds 
to castration, suggesting that the androgens are produced by the tumor cells (autocrine 
activity) (108). Novel agents which inhibit the intracellular production of androgens are 
currently being tested (109).  
The term “complete androgen blockade” refers to the combination of castration and 
AA. The rationale for such combined treatment is that castration does not affect the ~5% of 
androgen production that occurs outside the testis and that peripheral receptor blockade will 
improve the antitumor effect. The clinical benefits are probably limited (110). Patients with 
progressive PCa despite complete androgen blockade frequently experience temporary fewer 
symptoms and a decline in PSA concentration, a phenomenon referred to as the AA 
withdrawal response (111). 
 
1.1.8 Curative treatment strategies  
Localized tumors (cT1–2N0M0) 
The most intriguing problem facing early detected tumors is predicting whether the individual 
patient will benefit from curative treatment. Given the great variation in tumor biology 
discussed earlier, there is a high risk of both overtreatment and undertreatment. Because of the 
generally slow progression of PCa, watchful waiting with symptomatic treatment at 
progression is reasonable in many patients with limited life expectancy. Active surveillance of 
patients with early detected tumors and favorable prognostic factors followed by selective 
curative treatment of those with evidence of progression is another approach that theoretically 
may help to avoid overtreatment of indolent tumors and at the same time reduces the risk of 
undertreating aggressive tumors (112).  
If curative therapy is decided, several options are available. Radical prostatectomy is 
the only option shown in a randomized trial to increase PCa-specific survival compared with 
conservative management (58). The risk of dying from PCa was associated with positive 
margins in the surgical specimens. In the same study, a significant increase in overall survival 
was found in patients younger than 65 years. Radiotherapy, provided by external beams or 
internal implants (brachytherapy) or both, is generally accepted as being equally effective as 
prostatectomy in similar patients (113), although randomized studies have not been 
performed. The EAU regards cryotherapy (114) and high-intensity focused ultrasound 
ablation (115;116) as investigational therapies with curative potential (20). 
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The prognosis following curatively intended therapy for localized PCa is generally 
good. For patients diagnosed in the PSA-era, the 10-year mortality rate approximates zero in 
those with low-risk disease defined as PSA < 10 μg/L and GS < 7 and cT < 2b (117). In 
patients with increased risk of treatment failure related to unfavorable prognostic factors such 
as PSA > 10 μg/L, a GS  7 or cT2b–c, radiotherapy + castration-based HT has been shown to 
increase overall survival and PCa-specific survival compared with radiotherapy alone (118). 
A similar benefit from HT combined with prostatectomy has not been found, although 
adjuvant HT following prostatectomy may improve clinical outcomes in selected patients 
(119). Based on a relatively high risk of PCa-specific death in patients with PSA >10 μg/L 
and T2b–c and GS  7 following curatively intended therapy, these patients were recently 
suggested as candidates for trials exploring systemic treatments adjuvant to standard radical 
prostatectomy or radiotherapy + HT (120). Patients with cT1–2 tumors that are upstaged to pT3 
or have tumor involvement in the resection margin following prostatectomy may benefit from 
adjuvant radiotherapy to the prostatic bed (121;122). Local salvage options in selected 
patients with PSA recurrence after primary therapy include radiotherapy following 
prostatectomy and prostatectomy following radiotherapy (123).  
In summary, the current standard curative treatment for localized PCa is radical 
prostatectomy or conformal dose-escalated radiotherapy (74–78Gy). The EAU recommends 
adjuvant HT for poorly differentiated tumors treated by radiotherapy (20).  
 
Locally advanced tumors (cT3–4pN0M0  or  cT3–4pNXM0) 
Patients with locally advanced tumors at diagnosis are as previously accounted for at 
substantial risk of dying from PCa within 10 years if left untreated. They will usually benefit 
from multimodal therapy including local and systemic treatment (Bousted, BJU, 2007). 
Curatively intended radiotherapy + HT is the standard treatment and has been shown to 
improve clinical outcomes compared with radiotherapy alone in several randomized trials (94-
98;104). Radiotherapy + AA has been shown to improve overall survival and PCa specific 
survival compared with AA alone (105). Primary prostatectomy may be an option in selected 
patients with small cT3a tumors (124). Primary palliative HT is reasonable in patients with 
short life expectancy. Lymph node-positive PCa is currently regarded as noncurable and 
standard treatment according to the EAU is palliative HT (20).  
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1.1.9 Advances in curatively intended radiotherapy 
Technological aspects 
The therapeutic challenge of radiotherapy for nonmetastatic PCa is to deliver an adequate 
dose to the tumor while avoiding toxicity to adjacent organs (i.e. rectum, bladder, urethra, and 
penile structures). Conventional external beam radiotherapy usually refers to two-dimensional 
treatment planning (125). Three-dimensional conformal external beam radiotherapy (Fig. 1.1) 
refers to CT-based three-dimensional planning systems that in combination with multileaf 
collimators in the gantry of the linear accelerators, allow for  reduction of treatment volumes 
for normal tissues compared with conventional radiotherapy (126). Modern intensity-
modulated radiotherapy (IMRT) increases the conformality further by inverse dose planning 
and intensity modulation of the beams (127). Brachytherapy is currently evolving as an 
alternative or supplement to external beam radiotherapy, and allows for conformal radiation 
of the prostate with a sharp decrease in dose outside the gland (125). 
 
Dose escalation  
Even though a dose–response relationship for PCa has been demonstrated (128), the optimal 
dose for different phenotypes of PCa has not been clarified. A previous review concluded that 
70–74 Gy seems appropriate for low-risk patients and that intermediate-risk patients benefit 
from dose-escalation to 78–80 Gy (129). The benefit from dose escalation in high-risk 
patients is less obvious because of the competing risks of failure, such as undetected 
locoregional or distant dissemination. The role of dose escalation has not been evaluated 
prospectively in the setting of adjuvant HT. The authors of the review concluded that it is 
unclear whether high-risk patients who receive combined treatment benefit from doses > 70 
Gy. Somewhat provocative to these conclusions, another study showed that a dose > 92 Gy is 
probably necessary to secure histologically verified eradication of locally advanced tumors 
(130). Abnormal postradiotherapy biopsies were reported recently in more than half of 
patients who received 70 or 78 Gy (131).  
Well-informed patients may prefer treatment with a lower risk of toxicity to a gain in 
overall survival. Significantly more patients chose 70 Gy over 74 Gy when they were 
informed about the increased risk of rectal toxicity associated with 74 Gy, despite a survival 
advantage for the higher dose (132). Conformal treatment modalities such as IMRT combined 
with image guided radiotherapy might allow dose escalation to more than 80 Gy without 
unacceptable toxicity (128;133;134). 
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Fig. 1.1. Conformal radiotherapy of prostate cancer. Anteroposterior field with the vesiculae seminalis included 
(upper left) and without the vesiculae seminalis (upper right) in the target volume arrangement. Lateral field with 
the vesiculae seminalis included (lower left) and without the vesiculae seminalis (lower right) in the target 
volume arrangement. Reprinted from International Journal of Radiation Oncology, Biology, Physics, Vol. 43, No 
4. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive 
radiotherapy or radical prostatectomy. Lilleby W, Fosså SD, Wæhre HR, Olsen DR. Page 737. Copyright (1999), 
with permission from Elsevier.      
 
Adjuvant treatment 
In patients with locally advanced PCa or localized PCa with poor prognostic factors, both 
castration-based HT (94-98) and nonsteroidal AA (104) combined with radiotherapy are 
associated with better clinical outcomes compared with radiotherapy alone; the benefits 
include improved overall survival. HT may be given neoadjuvant, concomitant and/or 
adjuvant to radiotherapy. In addition to the possible effects of HT on occult disseminated 
disease, neoadjuvant and concomitant HT has important local effects. Downsizing of the 
prostate gland associated with HT reduces the target volume and consequently lowers the 
dose to the rectum (135). HT is aslo associated with T-cell infiltration and apoptosis of PCa 
cells, which may enhance the radiotoxic effects (136).  
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 The optimal duration of HT is unclear. Two randomized trials have shown that, 
compared with six months of HT together with conventional radiotherapy  70Gy, 28 months 
(137) or 36 months (138) improves PCa-specific outcomes. Results from another study 
suggest that treatment for more than six years may benefit some patients (139).  
 D’Amico et al showed recently that even though radiotherapy + six months of HT 
improved overall survival compared with radiotherapy alone for localized unfavorable-risk 
PCa, this was not true for a subgroup of patients with moderate to severe comorbidity. Future 
studies should focus on identifying patients for whom the disadvantages of adjuvant treatment 
may outweigh the antitumor effects.  
   
Radiation of pelvic lymph nodes 
Instead of performing surgical staging before radiotherapy, many centers provide a whole-
pelvic radiation field (~50 Gy) to patients with a certain risk of lymph node involvement 
based on nomograms (21;140) followed by a boost to the prostate only. This practice is 
considered by many to be standard treatment after a randomized trial (RTOG 94-13) found 
increased progression-free survival following whole-pelvic radiotherapy + HT compared with 
prostate only radiotherapy + HT (141). However, a recent update of this trial showed that the 
difference in progression-free survival between the groups was no longer significant on 
prolonged follow-up (142). Preliminary results from another randomized trial (GETUG-01) 
did not indicate that whole-pelvic radiotherapy improves progression-free survival compared 
with prostate-only radiotherapy (143). Thus, the clinical benefits of whole-pelvic radiotherapy 
is uncertain and associated with controversies (144;145). Compared with radiation restricted 
to the prostate, whole-pelvic radiation is associated with increased risk of intestinal toxicity 
(142;146), which may be reduced if pelvic radiation is delivered by IMRT (147;148).     
 
1.1.10 Organ-specific morbidity and health-related quality of life (HRQoL) after 
curatively intended external beam radiotherapy 
The price for cure 
Faced with several treatment options expected to have similar curability rates, the 
posttreatment side effects are important measures for patients and clinicians to consider when 
choosing the treatment modality. The potential organ-specific side effects following curative 
treatment include impaired urinary, bowel, and sexual function. Furthermore, secondary 
cancers may develop following radiotherapy (149;150). Endocrine effects from adjuvant HT 
also add to the total load of morbidity (90;91). In addition to specific treatment-related or 
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disease-related effects, cancer and its treatment may influence other aspects of a person’s 
well-being, frequently referred to as HRQoL. Side effects and HRQoL can be assessed by 
physicians using predefined scales (151) or by the patients using validated instruments for 
self-reported outcomes (152).   
Randomized studies have not compared the side effects from radical prostatectomy 
and radiotherapy. The available data indicate a higher risk of erectile dysfunction and urinary 
incontinence following prostatectomy and a higher risk of irritative urinary symptoms and 
bowel dysfunction following radiotherapy (153;154). Brachytherapy is probably associated 
with less rectal toxicity and more urinary toxicity compared with external beam radiotherapy 
(153). These assumptions may not be representative for individual settings because of the 
large variety in patient selection and treatment conditions. Pelvic morbidity after curative 
local treatment may be confounded further by age-dependent comorbidity, disease 
progression, or HT.  Therefore, to estimate the proportion of morbidity that is caused directly 
by a specific local treatment, the optimal trial would have to include baseline data and a 
randomized control group of patients who receive no active treatment. No such study has been 
published. Therefore, the published estimates of risk for specific complications carry great 
uncertainty. The following section addresses the side effects related directly to external beam 
radiotherapy. 
 
Urinary function 
Subsequent to radiotherapy, acute inflammatory prostatocystitis may give rise to symptoms 
such as increased frequency, urgency, incontinence, retention, hematuria, and dysuria (155). 
These symptoms are often transitory, but consecutive damage of the urothelial cells may lead 
to consequential late side effects such as bladder fibrosis, strictures, sphincter damage, 
hemorrhagic cystitis/urethritis, and irritative cystitis/urethtritis. The most common urinary 
symptom following radiotherapy is probably increased frequency or urgency (155). Late 
genitourinary toxicity following radiotherapy appears to be relatively consistent over the first 
few years after radiotherapy (146;156). In a long-term longitudinal study, the self-reported 
incontinence on a group level was similar at the four- and eight-year follow-up, but increased 
significantly at the 15-year follow-up, without a similar increase in incontinence among 
controls from the general population (157). 
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Bowel function 
Radiotoxic injury of the rectum, sigmoid colon, and small intestine may lead to symptoms 
such as fecal leakage, flatulence, rectal bleeding, diarrhea, painful bowel movements, rectal 
urgency, increased frequency, tenesmus, and mucus discharge (158). Acute symptoms that 
occur during radiotherapy usually resolve, but long-term problems also occur (159). A recent 
longitudinal study found that late gastrointestinal symptoms often fade during the first five 
years after radiotherapy (146). Another study found no difference in self-reported bowel 
symptoms after radiotherapy for PCa at the four, eight, and 15-year follow-up, but the patients 
had significantly more symptoms compared with controls from the general population at all 
time-points (160). The risk of late bowel symptoms depends on dose (158), field size 
(146;161), and patient-related factors such as earlier gastrointestinal symptoms and abdominal 
surgery (162). Appropriate focus on conformality, and neoadjuvant HT (135) may allow for 
dose escalation without an unacceptable increase in gastrointestinal complications.    
  
 Sexual function 
Erectile dysfunction may be caused by radiation to the neurovascular bundles, internal 
pudendal arteries, and the proximal penile structures such as the crura of the corpora 
cavernosa and the penile bulb of the corpus spongiosum (163). The prevalence of erectile 
dysfunction following radiotherapy increases gradually for the first five years (164) most 
likely because of gradual fibrosis of the small vessels. Whether the radiotoxic process 
continues after five years is not clear. Fransson and Widmark found similar prevalences of 
erectile dysfunction at four and eight years of follow-up in a longitudinal study, but there was 
a tendency towards more general sexual problems at the later time (156).  
A review of articles that specifically addressed the risk of erectile dysfunction after 
radiotherapy found rates of 8–85% (165). Thus, it is impossible to estimate risk exactly based 
on the literature. Sildenafil was effective in approximately 50% of patients with erectile 
dysfunction after radiotherapy in a placebo-controlled, double-blind trial (166).   
 
1.1.11 Self-reported outcomes  
Self-reported multidimensional HRQoL assessment by validated instruments may provide 
knowledge about the patient’s own perception of health effects of cancer and its treatment that 
may differ from the physician’s views (167). In addition, physician-reported organ-specific 
symptoms may differ from the patient’s self-reported symptoms, as shown following pelvic 
radiotherapy for cervical cancer (168). Instruments for self-reported HRQoL and specific 
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symptoms may be generic, cancer specific, or cancer type specific (152). Longitudinal studies 
measure changes within self-reported outcomes over time; for example, in relation to specific 
interventions (164). Cross-sectional studies may provide useful information if the results are 
compared with those of reliable control groups; for example, with normative data from the 
general population (169-171).   
 Several studies have reported that generic HRQoL outcomes are similar between data 
from PCa patients following definitive radiotherapy and normative data from the general 
population (68;157;164;172;173). This may reflect that generic HRQoL instruments might be 
insensitive to cancer- or treatment-related symptoms. Furthermore, a response shift may occur 
among cancer patients (174) as they accept disease- or treatment-related symptoms as 
inevitable and do not integrate them into their perception of general quality of life. These 
assumptions were supported by a cross-sectional single-institution study at the NRH of 
patients at least one year following radical prostatectomy or radiotherapy (172). Specific 
organ-related post-treatment morbidity such as urinary incontinence, erectile dysfunction, and 
bowel distress did not independently predict global HRQoL in a multivariate analysis. On the 
other hand, poor urinary function, urinary bother, sexual function, and sexual bother were 
independently associated with worse generic HRQoL outcomes two years after diagnoses of 
PCa in a large American population-based study (173).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 29
1.2 Disseminated tumor cells (DTCs)  
1.2.1 Minimal residual cancer  
With a few exceptions, (e.g. testicular cancer), distant metastases usually exclude curative 
treatment of solid malignancies. M staging is the single most important prognostic factor at 
diagnosis. However, many M0 patients experience metastatic relapse following local treatment 
of the primary tumor (58). The principle explanations are unsuccessful local eradication of the 
tumor or the existence of occult metastatic tumor cells that have been shed from the primary 
tumor prior to primary treatment. The detection of tumor cells by sensitive methods such as 
ICC and polymerase chain reaction (PCR) have enhanced our understanding of the metastatic 
process and have resulted in comprehensive models for malignant spread and development of 
metastases (175). The cells detected by these methods are frequently referred to as 
“micrometastases”, “occult tumor cells”, or “minimal residual cancer”, which all refer to 
metastatic cancer that cannot be detected by routine diagnostic procedures (176). According 
to contemporary definitions, DTCs refer to tumor cells that are detected in the BM, and 
circulating tumor cells (CTCs) refer to tumor cells that circulate in the peripheral blood. 
Isolated tumor cells (ITCs) refer to minimal residual cancer cells in general.    
In theory, several clinical applications of such approach are possible. Detection of 
ITCs in M0 patients at diagnosis may predict the development of distant metastases despite 
successful local tumor eradication. If so, detection of the cells may identify high-risk patients 
who may not benefit from local therapy alone, but who may benefit from adjuvant therapy in 
addition to local eradication of the tumor. Furthermore, patients without ITCs may be spared 
for adjuvant treatment. Characterization of the cells may also guide adjuvant therapies 
directed towards specific targets within the cells. In posttreatment monitoring, detection of 
isolated tumor cells may be an early surrogate marker of treatment failure in patients 
characterized as “tumor free” by conventional biochemical and diagnostic methods. 
 
1.2.2 Technological aspects  
ITCs are detected mainly by ICC using monoclonal antibodies or by PCR with cancer-specific 
or tissue-specific transcripts. The main advantage of ICC is maintenance of cell morphology 
and thus the possibility of further biological and morphological characterization of the cells 
with consequent exclusion of false-positive immunostained noncancer cells (Fig 1.2) (177).  
Direct quantification of ICC-detected ITCs can be performed. Among several factors, the lack 
of true cancer-specific molecular targets remains a problem for the specificity of PCR-based 
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techniques (178). Furthermore, quantification of tumor cells is difficult, although 
contemporary real-time PCR partly may solve this problem (179).  
Most assays to detect minimal residual cancer in peripheral blood or the BM include 
enrichment of mononuclear cells (lymphocytes and monocytes) by density centrifugation 
(180) because tumor cells are usually trapped in the mononuclear cell layer. In practice, the 
amount of mononuclear cells that can be investigated following density centrifugation is 
restricted to the 106 level with ICC and the 107 level with PCR. The number of mononuclear 
cells investigated by ICC can be increased to the 107 level following further enrichment of 
tumor cells by negative and/or positive immunomagnetic separation techniques that apply 
paramagnetic microparticles coated with antibodies to leucocytes or tumor cells (181;182).   
The application of monoclonal antibodies directed against cytokeratins has become the 
mainstay for ICC detection of DTCs in the BM from patients with carcinomas (183). 
Cytokeratins are proteins in the cytoskeleton of epithelial cells that are not normally expressed 
in hematopoietic cells. Anti-PSA antibodies have also been applied for detecting PCa cells, 
but these are less sensitive than anticytokeratins (184). The most frequent anticytokeratin 
antibodies in use for DTC detection are AE1/AE3 (185), A45/B-B3 (186), and CK2 (187). 
AE1/AE3 and A45/B-B3 are assumed to be pancytokeratin antibodies (because they react 
with several subtypes of cytokeratins), whereas CK2 reacts only with cytokeratin 18. The 
importance of excluding false-positive cells by standardized morphological evaluation of all 
immunostained cells has been emphasized (177).  
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1.2.3 Clinical findings and prognostic impact 
The clinical impact of detecting minimal residual cancer has been studied most extensively in 
breast cancer: In a pooled analysis of 4703 patients with a median follow-up of 62 months, a 
positive DTC status in the BM at diagnosis was independently associated with increased risk 
of death from any cause, death from breast cancer, disease recurrence, and distant metastases 
(188). Positive DTC status at diagnosis was associated with large tumor size, high 
histopathological grade, lymph node metastases, and negative hormone receptor status. 
Smaller studies have demonstrated a correlation between DTCs in the BM at diagnosis and 
treatment failure in other solid tumors such as colorectal cancer (189), lung cancer (190;191), 
malignant melanoma(192), osteosarcoma (193), and PCa (70;72;76).  
 Compared with DTCs in the BM, finding of CTCs in peripheral blood is generally less 
frequent (73;74;194), and seems to be less predictive of the clinical course (194). The reason 
may be that tumor cells circulate in the blood only for a limited time before settling at distant 
sites. Interestingly, the predictive impact of DTC detection was reduced in cohort of patients 
Fig. 1.2  
Examples of morphological features of 
disseminated breast cancer cells categorized as 
tumor cell (A and B), uninterpretable cell (C 
and D), probable hematopoietic cell (E and F), 
and hematopoietic cell group (G and H). 
Reprinted from Clinical Cancer Research Vol. 
10. The prognostic value of isolated tumor 
cells in bone marrow in breast cancer patients: 
Evaluation of morphological categories and 
the number of clinically significant cells. 
Naume B, Wiedswang G, Borgen E, Kvalheim 
G, Karesen R, Qvist H, Janbu J, Harbitz T, 
Nesland JM. Page 3093. Copyright (2004), 
with permission from the American 
Association for Cancer Research, Inc.  
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when the number of mononuclear cells investigated was increased from 2´106 to 6´106. The 
explanation may be that a certain load of DTCs is necessary for the development of distant 
metastases.   
The appearance of DTCs in the BM following primary therapy for breast cancer (195) 
or PCa (73) seem to predict subsequent clinical progression, suggesting a possible role for 
monitoring patients during follow-up. In addition, quantification of CTCs by a commercial 
automated method (CellSearch) can predict the clinical course in both metastatic breast cancer 
(196) and castrate-resistant PCa (197).  
    
1.2.4 Disseminated prostate cancer cells in the BM 
Because about 90% of PCa patients with distant metastases have skeletal lesions (30), the BM 
seems to be an appropriate site to look for minimal residual cancer. This section presents 
published studies that have detected DTCs in the BM of PCa patients except for those studies 
included in the current thesis (70;71). The inconsistent results in these studies probably reflect 
different methods and lack of standardization.   
Oberneder et al assessed DTC status in 84 patients with T1–4N0–1M0–1 PCa by ICC 
using the monoclonal antibody CK2 (198). The prevalence of positive DTC status was 36%. 
Compared with DTC-negative patients, DTC-positive patients had a significantly higher risk 
of extracapsular tumor extension, distant metastases, and unfavorable histological grade. In 
patients with well- or moderately differentiated tumors (WHO grading), DTC-positive 
patients had a higher risk of lymph node metastases.  
Pantel et al used the same method and found DTCs in 55% of 44 cT3–4pNXM0 patients 
(199). BM findings were not associated with tumor volume, the GS, or PSA concentration. 
The same research group performed repeated BM aspirations in 36 T3–4pNXM0 patients who 
received HT (200). The prevalence of positive DTC status was 58% before and 17% after 3–5 
months of complete androgen blockade, indicating that DTC detection may be used as a 
surrogate marker of the response to treatment.  
Using antibodies against cytokeratins 8 and 18, Mueller et al detected DTCs in 45% of 
67 patients with cT1–4N0–1M0 PCa; 37 of these patients had received HT before BM aspiration 
(184). Positive DTC status was independent of PSA concentration, T-category, and HT. Only 
12% of cytokeratin-positive cells coexpressed PSA according to a dual staining procedure. 
Most of the cytokeratin-positive cells were cytogenetically aberrant according to fluorescence 
in situ hybridization quantification of chromosomes 1, 7 and 8, implying a malignant origin of 
these cells.     
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Weckermann et al detected DTCs using CK2 before radical prostatectomy in 219 
patients with pT1–3pN0M0 PCa (75). The prevalence of positive DTC status was 24%. Positive 
DTC status was not associated with the GS, pT category, perineural invasion, lymphatic 
invasion, or pretreatment PSA concentration, or with lymph node status when 47 N1 patients 
were included. Ploidy was determined in 58 of the patients but was not associated with DTC 
status. Because cytokeratin 18 is probably downregulated in adenocarcinomas (201), the same 
research group performed a second study (76) that included 82 patients from the first study, 
six of whom had regional lymph node metastases. BM samples from these patients were 
incubated with the pancytokeratin antibody A45/B-B3 in addition to CK2. The prevalences of 
positive DTC status were 24% for CK2 and 40% for A45/B-B3, but the DTC status was not 
associated with other prognostic variables. A45/B-B3-positive DTC status, but not CK2-
positive DTC status, independently predicted PSA recurrence after four years median follow-
up.  
In 2003, Lilleby et al published the first results of DTC detection in PCa patients 
referred to the NRH for radiotherapy (73). The pancytokeratin antibodies AE1/AE3 identified 
positive DTC-status before definitive radiotherapy in 21% of 66 cT1–4pN0M0 patients, but 
positive status was not associated with the GS, cT category, or pretreatment PSA. The Pre-
radiotherapy DTC status did not predict clinical progression-free survival following 
radiotherapy at median five years of follow-up. BM was also aspirated in 60 of the patients 
25–57 months after radiotherapy. Positive post-radiotherapy DTC status was found in 20% 
and was associated with an increased risk of clinical progression compared with patients with 
negative post-radiotherapy DTC status, supporting that DTC detection may be useful for 
monitoring the effects of therapy.   
Kollermann et al used A45/B-B3 to detect DTCs in the BM before neoadjuvant 
complete androgen blockade followed by prostatectomy in 193 cT1–3pNXM0 PCa patients (72). 
Positive DTC status was found in 45% but was not significantly associated with pretreatment 
PSA concentration, cT category, pT category, or the GS in needle biopsies or prostatectomy 
specimens. However, positive DTC status was an independent predictor of PSA recurrence 
after a median 61 months of follow-up. 
Wood et al applied an RT-PCR assay that targeted PSA mRNA in the BM before 
prostatectomy in 86 pT1–3pN0–1M0 PCa patients (202). Positive DTC status was found in 45% 
of patients and was associated with extraprostatic disease in the surgical specimens and 
pretreatment PSA  10μg/L, but not with the GS (< 7 versus  7) in needle biopsies or 
surgical specimens. Positive DTC status predicted PSA recurrence in a univariate analysis 
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after a mean follow-up of 15 months, but not in multivariate analysis when PSA concentration 
at diagnosis was included. The same research group later reported that 96% of 46 patients 
with PSA mRNA in their BM also had ICC-detected cytokeratin-positive DTCs in their BM 
(203). Double staining with an antibody directed against the proliferation marker Mib-1 was 
performed in a subgroup of 38 patients and showed positive findings in 68% of these, 
indicating that these cells were in the active cell cycle. In a third publication, PSA mRNA was 
found in 79 of 244 (32%) patients with cT1–2 PCa before prostatectomy (204). Double ICC 
staining for cytokeratins and Mib-1 was performed on 58 of the RT-PCR-positive patients. 
Cytokeratine-positive cells were found in all patients and Mib-1 positive cells were found in 
36% of the patients. The presence of proliferating cells was associated with the GS in the 
prostatectomy specimens but not in needle biopsies or with other variables. Patients with 
proliferating DTCs had a significantly higher risk of PSA recurrence compared with patients 
with non-proliferating DTCs.     
Several papers on DTCs in the BM and peripheral blood of PCa patients have been 
published from the University of Washington in Seattle (74;181;205-208). Both RT-PCR and 
ICC have been applied. Isolation of tumor cells and increased sensitivity of their assays have 
been achieved using a combination of positive and negative immunomagnetic selection 
techniques (181). After enriching the tumor cell fraction, the group found that 49% of the 
DTCs in the BM expressed Telomerase (208). A later publication reported on PSA RT-PCR 
and ICC using the antibody BerEP4 against the epithelial marker EpCam in BM aspirates 
(74). Before prostatectomy, 49 of 154 (32%) were positive for PSA mRNA and 121 of 162 
(75%) were positive for BerEP4. Eighty-six (71%) of the BerEP4 positive patients had PSA-
expressing cells in the BM, which were identified by positive findings on PSA RT-PCR or 
PSA ICC. In a subgroup of 32 patients who had no PSA recurrence at least one year after 
prostatectomy, 12% were positive for PSA mRNA and 47% for BerEP4, implying the 
existence of dormant tumor cells in these patients. In the same study, a control group included 
27 men who were assumed to be without PCa based on PSA concentration < 2.5 μg/L. 
Among these, one (4%) had PSA mRNA in his BM and three (11%) had BerEP4-positive 
cells. 
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1.2.5 Minimal residual prostate cancer in peripheral blood and lymph nodes  
Peripheral blood 
Before settling in the BM, tumor cells must migrate through the bloodstream. Tumor cells can 
also circulate in the blood secondarily to metastases in distant organs. Because a venous 
puncture is more convenient than a BM aspiration, several studies have identified CTCs in the 
peripheral blood of PCa patients. Many of these studies have applied RT-PCR as the detection 
method. A positive finding before prostatectomy in some studies been associated with 
biochemical progression (209-212) and in one study with development of distant metastases 
(213). However, these findings have not been supported by other studies (206;214;215). 
Inconsistent results have also been reported on the relationship between CTCs and other risk 
factors. Shariat et al concluded that positive PSA RT-PCR in peripheral blood 6–8 weeks 
after, but not before prostatectomy predicts PSA-based failure (216). In progressive castrate-
resistant PCa, quantification of CTCs by the automated CellSearch system can provide 
prognostic information (197). 
    
Lymph nodes  
In addition to unrecognized hematogenous dissemination, occult spread to regional lymph 
nodes probably contributes to treatment failure after radical local treatment. Several studies 
have shown that occult tumor cells can be detected by ICC or RT-PCR in lymph nodes that 
are judged to be free from cancer by standard pathological evaluation (26;27;210;211;217-
226). Two relatively large prospective studies with long-term follow-up have shown that 
positive findings are predictive of clinical survival endpoints following prostatectomy. Shariat 
et al investigated lymph node specimens from 199 prostatectomized patients classified as 
pT3pN0 following extended lymph node staging (27). Occult tumor cells were detected by RT-
PCR targeting the prostate-specific human glandular kallikrein (hK2) and ICC with antibodies 
against PSA, cytokeratin, and hK2. The lymph node status was positive for tumor cells in 
13% by ICC and 20% by RT-PCR. Positive findings by both methods were associated with 
increased risks of PSA recurrence, development of distant metastases, and death from PCa. 
Pagliarulo et al included 274 pT3N0–1 patients who had been treated by radical prostatectomy 
and surgical lymph node staging and followed them for 13 years, median (26). Occult tumor 
cells were detected by ICC in lymph nodes from 24 of 180 patients (13%) who were judged to 
be pN0 following routine pathological evaluation. Patients with pN0 disease with occult lymph 
node metastases had a higher risk of PSA recurrence and death from any cause compared with 
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pN0 patients without occult lymph node metastases. The recurrence rates for pN0 patients with 
occult lymph node metastases and pN1 patients were similar.    
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Chapter 2: The current thesis 
 
2.1 Introduction 
The work presented in this thesis began in October 2004. At that point, dose escalation to 
74Gy and adjuvant castration-based HT for high-risk patients (94) was the standard treatment 
when radical radiotherapy was given for PCa at the NRH. From 1989 to February 1996, 
radiotherapy was given as monotherapy with doses  70Gy. Most patients eligible for 
radiotherapy were not considered to be candidates for surgical prostatectomy, because of 
either locally advanced tumor growth or other factors such as comorbidity or age. Radical 
radiotherapy was only offered to patients who were considered to be without lymph node 
metastases based on surgical staging.  The five-year clinical outcomes from those who were 
treated in that period have been published (227) as well as the HRQoL findings at least one 
year after radiotherapy (172). Because of the long natural history of PCa and because 
relatively few studies had been published in 2004 including 10-year clinical outcomes 
following radiotherapy for pN0 PCa (228-230), a repeated follow-up of the patients was 
needed. Paper I comprises the mature 10-year clinical outcomes for all 203 patients who 
received definitive radiotherapy at the NRH from 1989 to February 1996 and the self-reported 
HRQoL outcomes in the surviving patients (68).  
During 1996–2002, definitive radiotherapy was usually given at the NRH within the 
framework of the seventh trial of the Scandinavian Prostate Cancer Group (SPCG-7), which 
compared AA with or without radiotherapy for locally advanced or localized high-grade PCa 
(105). Comparison of clinical outcomes and HRQoL among these patients has been 
performed by the SPCG-7 study group and was outside the scope of this thesis. However, to 
expand the knowledge about the consequences of combined radiotherapy and long-term AA, 
there was a need to compare HRQoL between patients who received such treatment and age-
matched controls from the general population. Increases in serum testosterone and estradiol 
concentrations have been reported following one and two years of AA treatment (99;231). 
Hormonal changes in patients who have used AA for a longer time had not been reported 
before the planning of this thesis. A prolonged increase in serum estradiol concentration may 
be important because of the possible increase in the risk of cardiovascular morbidity (93). In 
paper II, self-reported outcomes at the five-year follow-up in patients included in the 
radiotherapy + AA arm at the NRH were compared with self-reported outcomes from age-
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matched controls in the general population. Longitudinal changes in sex hormone 
concentrations during the five years of AA treatment were also explored.   
The “micrometastases project” was established at the NRH early in the 1990s to detect 
and characterize single metastatic tumor cells in patients without overt metastases. The 
theoretical rationale was that such cells might represent early evidence of metastatic disease 
and, if so, would provide prognostic information and be potential targets for adjuvant therapy. 
ICC has been used for DTC detection, and the project has made important contributions to 
improving and standardizing the methods (177;182;232-235). The project has also contributed 
greatly to the comprehensive body of evidence that DTCs in the BM predict treatment failure 
in breast cancer (195;236). Between 1994 and 2007, PCa patients were asked to donate BM 
samples for DTC detection before and after radiotherapy. Preliminary results showed a 
relationship between the presence of DTCs after radiotherapy and clinical progression-free 
survival but no relationship between the presence of DTCs before treatment and five-year 
clinical outcomes (73). Weckermann et al showed previously that DTCs detected by ICC 
predict PSA-based recurrence following radical prostatectomy (76). In both studies, the 
detection of DTCs was independent of the standard prognostic factors PSA concentration, the 
GS, and T-category. The rationale for paper III (70) was based on the hypothesis that 
expansion of the patient group would show an association between DTCs and established 
prognostic factors, and that longer follow-up would show an association between DTCs and 
the development of distant metastases following radiotherapy. In paper IV (71), the 
prevalence of DTCs in the BM after definitive radiotherapy with or without HT were 
investigated.   
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2.2 Study aims 
Based on the background outlined above, the current thesis was motivated by the following 
study aims:  
 
1. To assess mature 10-year clinical outcomes following definitive radiotherapy  70 Gy as 
monotherapy for PCa.  
 
2. To assess long-term self-reported outcomes following definitive radiotherapy as 
monotherapy for PCa and to compare the findings with normative data from the general 
population.  
 
3. To assess self-reported outcomes in PCa patients following definitive radiotherapy + long-
term adjuvant treatment with an oral nonsteroidal AA and to compare the findings with those 
in age-matched controls from the general population.   
 
4. To assess longitudinal changes in sex hormone concentrations in PCa patients who have 
used an oral nonsteroidal AA continuously for five years. 
 
5. To assess the prevalence of DTCs in the BM of patients with untreated M0 PCa using a 
standardized ICC method and to explore the possible associations between DTC status before 
treatment and clinical, biochemical, and histopathological variables.  
 
6. To explore whether the appearance of DTCs in the BM of PCa patients before definitive 
radiotherapy predicts clinical outcomes.  
 
7. To assess the prevalence of DTCs in the BM of clinically progression-free PCa patients 
after definitive radiotherapy with or without adjuvant HT.  
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2.3 Patients and methods 
The current thesis comprises four substudies represented by papers I–IV. A total of 466 men 
were included with some overlap between the substudies (Fig. 2.1). They had all been referred 
to the Department of Oncology, NRH because of newly diagnosed M0 PCa during 1989–
2004.   
 
 
 
 
2.3.1 TNM staging 
The clinical status was T1–4pN0M0 in all patients except 24 who were T1–4pNXM0. The latter 
patients were considered to have a low risk of lymph node metastases based on pretreatment 
PSA concentration < 10μg/L. Pelvic lymphadenectomy had been performed in all the other 
patients to verify the pN0 status, which was required to receive the curatively intended 
radiotherapy. The cT-category had been assessed by digital rectal examination. Chest X-ray 
and technetium bone scan, with supplementary skeleton X-ray or MRI if indicated, had been 
performed to confirm the M0 status in all patients.  
 
2.3.2 Histopathological parameters 
At referral, all PCa diagnoses were confirmed routinely by histopathological review of the 
patients’ biopsies at the Department of Pathology, NRH. The patients in paper I received 
treatment in 1989–1996, and their biopsies were graded originally according to WHO grading 
system (40). These had been regraded using the GS in a previous follow-up study (227). For 
papers III and IV, all available biopsies were regraded to provide a GS by one experienced 
pathologist using new guidelines (34). For paper III, the “percentage of Gleason pattern 4/5”, 
“percentage positive biopsies”, and “percentage tumor length in all cores” (35;36) were 
Paper I 
N = 203 
Paper II 
N = 86 
Paper III 
N = 266 
Paper IV 
N = 130 
Total 
N=466 
Fig. 2.1. Distribution of patients between substudies. 
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assessed from needle biopsies. When there were two or more separate foci of cancer in the 
same needle, the uninvolved tissue between the foci was included in the assessment of 
“percentage tumor length in all cores”. 
 
2.3.3 Biochemical parameters 
An in-house time-resolved fluoroimmunometric assay for PSA was applied until June 2006  
(237), and the AutoDELFIA ProStatus PSA Free/Total kit (PerkinElmer, Waltham, 
Massachusetts) was used after June 2006. The two methods are identical in format and 
calibration, and both have a detection limit of 0.05 μg/L.  
Testosterone concentration was measured with a Spectria-coated tube (Orion 
Diagnostica, Espoo, Finland). The concentrations of estradiol and sex hormone-binding 
globulin (SHBG) were measured using the Autodelfia method (Wallac, Turku, Finland), and 
the concentrations of follicle stimulating hormone (FSH) and LH were measured by the 
Access method (Beckman, Fullerton, California). The coefficients of variation were less than 
10% for each method. The reference ranges were testosterone 8–35 nmol/L, estradiol < 0.13 
nmol/L, SHBG 25–65 nmol/L, LH < 12 IU/L and FSH < 12 IU/L. 
 
2.3.4 Treatment 
Radiotherapy 
Most of the included patients received curatively intended external beam radiotherapy with 
target-doses of 64–74Gy depending on the year of treatment. The standard dose at the NRH 
was 66 Gy until 1996, 70 Gy in 1996–2000 and 74 Gy thereafter. A four-field box technique 
(two opposing anterior–posterior fields and two opposing lateral fields) was used. In 1989–
1994, multiple rectangular and triangular shielding blocks based on two-dimensional CT 
imaging were used. In August 1994, a modification was introduced that used a multileaf 
collimator and a three-dimensional CT planning system (Helax, Uppsala, Sweden) (Fig. 1.1). 
The gross tumor volume included the prostate and seminal vesicles. To account for 
microscopic disease, the clinical target volume comprised the gross tumor volume and an 
additional margin of 10 mm. The planning volume included the clinical target volume and a 
margin of another 10 mm to account for organ motion and setup errors. In addition, the 
irradiation field encompassed the planning volume and a margin of 5 mm to account for the 
penumbra so that the irradiation field in general added 25 mm to the gross tumor volume 
except that the posterior field margin towards the rectum added a maximum of 20 mm to the 
gross tumor volume up to 1996 and 10-15 mm thereafter. For tumors not involving the 
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seminal vesicles, the gross tumor volume was reduced to encompass only the prostate after 50 
Gy. All patients received megavolt photon energy, 15 MV, with daily fractions of 2 Gy, five 
days per week. The dose was prescribed on the central axis at the projected center of the target 
volumes, and from 1992 with regard to the reference point in the International Commission on 
Radiation Units and Measurements report number 50 (238).  
 
Hormone treatment 
From March 1996, most radiotherapy-treated patients received neoadjuvant, concomitant, and 
adjuvant HT if they had cT3–4, a PSA concentration > 20 μg/L, or intermediate or poorly 
differentiated tumors (WHO grade 2 or 3). During 1996–2002, patients had been included in 
the SPCG-7 study (105). These patients received neoadjuvant complete androgen blockade for 
three months (flutamide 250 mg ´3 + leuproreline 3.75 mg/month) followed by definitive 
radiotherapy and continuous nonsteroidal AA medication with flutamide 250mg ´3 or 
bicalutamide 150 mg ´1, or the same AA treatment without radiotherapy. Patients not 
included in the SPCG-7 study received medical castration with a GnRH agonist for two years 
(three months of neoadjuvant) or later for three years (six months of neoadjuvant). An oral 
nonsteroidal AA was given in the first month to avoid flare symptoms. The latter treatment 
became standard when the SPCG-7 trial was closed to inclusion.  
 
2.3.5 Follow-up 
Following primary therapy, patients were followed regularly by their local urologist in 
cooperation with their family doctor and the Department of Oncology, NRH. Most of the 
patients revisited the Department of Oncology’s outpatient ward once or more during follow-
up for clinical evaluation. All patients included in papers II and IV were examined at the 
Department of Oncology at the last follow-up in these substudies. 
 
2.3.6 Collection of clinical data  
Clinical data relating to the pretreatment variables were collected from patients’ files at the 
NRH. Survival status on the cutoff date of each of the two follow-up studies in papers I and 
III was retrieved from the Central Population Registry based on the unique 11-digit personal 
identification number. The cause of death was determined retrospectively by reviewing the 
hospital records and by contact with the responsible local clinicians. These sources also 
provided information on eventual date and type of progression. 
 
 43
2.3.7 Definitions of clinical outcome 
The endpoints overall death and overall survival were related to death from any cause. Cause-
specific death and cause-specific survival related to death due to PCa, death due to 
complications from treatment of PCa, or death from unknown causes in patients proven to 
have progressive castrate-resistant PCa. Clinical progression was defined as local or distant 
progression. Distant progression was defined as radiological evidence of distant metastases 
and local progression as clinically detectable growth of the prostate gland or loco-regional 
lymph nodes. In accordance with the Houston definition, PSA recurrence (called biochemical 
failure in paper III) was defined as an increase in PSA concentration of at least 2 μg/L above 
the nadir (defined as the last nonrising value) (53). In addition, any secondary therapeutic 
intervention based on increasing PSA concentration before the criterion was fulfilled was 
scored as PSA recurrence at the time of intervention. PSA recurrence was not evaluated as an 
endpoint in paper I because routine follow-up did not include assessment of PSA 
concentration during 1989–90.  
 
2.3.8 Instruments for self-reported outcomes 
The following validated questionnaires were applied in papers I and II (see appendix). They 
were chosen because of satisfactory psychometric properties and available normative data. 
 
The European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Instrument (QLQ-C30) 
The QLQ-C30 measures general HRQoL in cancer patients and comprises 30 items; 28 of 
these are scored on a 4-point Likert scale (239;240). Five multi-item functional scales 
measure physical function (five items), role function (two items), emotional function (four 
items), cognitive function (two items), and social function (two items). Nine symptom 
scales/items measure fatigue (three items), nausea and vomiting (two items), pain (two items), 
dyspnoea (one item), insomnia (one item), appetite loss (one item), constipation (one item), 
diarrhea (one item), and financial difficulties (one item). In addition, global health status and 
QoL are assessed by two separate items scored on a 7-point Likert scale ranging from very 
poor to excellent. The scores are combined into a global HRQoL scale (called GlobQL in 
paper I). All raw scores are linearly transformed into scales ranging 0–100 (241). Higher 
scores in global HRQoL and the functioning scales reflect better global HRQoL and better 
function. Higher scores in the symptom scales/items reflect more symptoms. The Norwegian 
version of the QLQ-C30 has shown satisfactory internal consistency in a study that provided 
 44
the normative data from the Norwegian general population (170). The QLQ-C30 version 3.0 
was used in paper I. 
 
The Short Form-36 (SF-36) 
The SF-36 is a widely used instrument for assessing HRQoL in general (242). It comprises the 
eight multi-item HRQoL domains physical functioning (10 items), role limitations due to 
physical problems (four items), bodily pain (two items), general health perception (five 
items), vitality (four items), social functioning (two items), role limitations due to emotional 
aspects (three items), and mental health (five items). These are combined into two summary 
scores: the physical component summary and the mental component summary (243). 
Dimension scores are transformed to a scale ranging 0–100 (244). The summary scores are 
transformed by linear T-score transformation so that the general population has a mean of 50 
and standard deviation of 10 (245). Higher domain scores represent better function. The 
Norwegian version has good internal consistency (246). The SF-36 version 1.0 was used in 
paper II. 
 
The Brief Male Sexual Function Inventory (BSFI) 
The BSFI comprises 11 items that are combined into three multi-item functional domains: 
sexual drive (two items), erections (three items), and ejaculation (two items); one domain for 
sexual problem assessment (three items); and one single-item domain that measures overall 
sexual satisfaction (247). The items are scored on a five-point Likert scale (0–4). Higher 
scores represent better function, fewer problems, and a higher degree of satisfaction with 
one’s sex life. 
 Based on face validity, the respondents were considered to have complete erectile 
dysfunction if they responded “not at all” to question #4: “Over the past 30 days, when you 
had erections how often were they firm enough to have sexual intercourse?” They were 
considered to have lack of sexual drive if they responded “low” to question #2: “During the 
past 30 days, how would you rate your level of sexual drive?” Sexual dissatisfaction was 
identified if the patient was “very dissatisfied” or “mostly dissatisfied” with his sex life the 
past 30 days (question #11).  
The Norwegian version of the BSFI showed good internal consistency in a recent 
study of Norwegian men from the general population, which provided the normative mean 
scores in 10-year age categories for paper I (171). Published American normative data 
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provided the age-adjusted responses to single items (248). The BSFI was used in papers I and 
II.  
 
The University of California, Los Angeles Prostate Cancer Index (PCI)  
The PCI addresses general and organ-related HRQoL in patients treated for PCa (249). Scores 
are linearly transformed into scales ranging 0–100, which are based on raw scores from 3–6 
point Likert-scales. Higher scores reflect better function and less bother. Normative data for 
American men without PCa have been published (250). 
For paper I, domains from the PCI relating to urinary function (five items), urinary 
bother (one item), bowel function (four items), and bowel bother (one item) were used. The 
bowel function domain of the PCI does not cover fecal control and the use of pads because of 
fecal leakage. Two ad hoc questions were added to cover these aspects, as fecal leakage can 
be an important side effect of radiotherapy (Table 3, paper I).  
  
The Hospital Anxiety and Depression Scale (HADS)  
The HADS was developed to measure symptoms of depression and anxiety in patients with 
somatic illnesses (251). The instrument comprises 14 items scored on a 4-point Likert-scale 
(0–3). The scores for seven items are added up to give the depression score (0–21), and seven 
different items are summed to give the anxiety score (0–21). Caseness of depression and 
anxiety are defined as a score of  8 within each scale. This cutoff point provides the best 
balance between sensitivity and sensibility in most studies (252). The basic psychometric 
properties of the Norwegian version are considered satisfactory based on a large sample from 
the Norwegian general population (253). The HADS was used in paper II.  
 
The Fatigue Questionnaire (FQ)    
The FQ measures mental (four items) and physical (seven items) features of fatigue on a 4-
point Likert-scale (0–3) (254). Mental fatigue and physical fatigue scores are derived from the 
sums of the scores within each scale (0–12 and 0–21, respectively). Total fatigue is the sum of 
all 11 items (0–33). Two additional questions are asked about the duration and extent of the 
symptoms. Caseness of chronic fatigue is defined as the sum of dichotomized scores (0–1 = 0, 
2–3 = 1) of > 4 and duration of six months or more (255). The Norwegian version was shown 
to have good internal consistency in a study of the Norwegian general population (256). The 
FQ was used in paper II. 
 
 46
Missing responses 
Missing responses within a domain were replaced by the mean of the completed items in that 
domain if at least half of the items were scored. In other cases, domain scores were considered 
as missing (257). 
 
2.3.9 Normative data and control groups 
HRQoL 
In paper I, the data for patients who had been treated by definitive radiotherapy were 
compared with published, age-adjusted normative data from the general population 
(170;171;248;250). In paper II, data for age-matched control cohorts were retrieved from the 
general Norwegian population: Using public data lists, the NRH had previously collected 
several samples of normative data from the general population to be used for comparisons 
with cancer patients. In 2004, a sample of 2100 men aged 50 to 79 years received a 
questionnaire including the BSFI, and 756 (36%) responded. In 2005, a sample of 1380 males 
of the same age range received a form including the HADS and the FQ, and 473 (34%) 
responded. Respondents reporting cancer were excluded. Based on these samples, the BSFI 
data for two age-matched controls within the same five-year category for each patient were 
retrieved, and the HADS and FQ data for one control for each patient were retrieved. 
Normative cases for the SF-36 were selected from the Living Condition Study of 2002 
performed by Statistics Norway on a representative sample of the population. From 1028 men 
aged 50 to 79 years, we selected two cancer-free controls per patient, also age-matched in 
five-year categories.  
 
Survival 
To compare 10-year overall survival in PCa patients treated by radiotherapy monotherapy 
with that of men from the general population (paper I), Statistics Norway constructed a 
control cohort using the following method. Three age-matched men for each nonemigrating 
patient were identified randomly. The eligible controls had to be alive the year radiotherapy 
was started in the corresponding case. The year of birth and year of death for each anonymous 
control were made available to the first author.  
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2.3.10 Detection of DTCs  
Aspiration and preparation of BM   
Local anesthesia was applied, a small skin incision was made, and 20–30ml of BM was 
aspirated from one of the posterior iliac crests during the early phase of the study (paper III) 
and later from both sides (paper IV). Fresh aspirates were diluted 1:1 in PBS (PAA 
Laboratories, Pasching, Austria). Mononuclear cells were isolated by density centrifugation 
using Lymphoprep (Axis Shield, Oslo, Norway) and washed twice in PBS with 10% FCS 
(PAA Laboratories). Cytospins were made by centrifuging the mononuclear cells onto 
polylysine-coated glass slides, each containing 5´105 cells. The slides were air-dried overnight 
and stored at –80ºC until immunostaining was performed.  
 
Immunostaining 
The cytospins were defrosted and fixed for 10 minutes in acetone. Four cytospins were 
incubated in a moist chamber with the pancytokeratin mononuclear antibodies AE1/AE3 
(Chemicon International Inc.) at a concentration of 20 μg/ml for 30 minutes. The visualization 
step included the alkaline phosphatase/anti-alkaline phosphatase reaction, and the slides were 
counterstained with hematoxylin to visualize the nuclear morphology. Another four spins 
were incubated with an isotype-specific irrelevant monoclonal antibody as the negative 
control (177). Before 1999, only one negative control spin was made. The positive control 
was performed by producing cytospins with BM from healthy volunteers to which 
cytokeratin-expressing tumor cell lines were added.  
 
Morphological characterization of immunostained cells 
The cytospins were screened manually for immunostained cells in the early phase of the study 
and automatically later (233). To distinguish tumor cells from immunostained hematopoietic 
cells, all stained cells were evaluated by an experienced pathologist using published 
guidelines (177). If the sample contained at least one stained cell that was judged to be a 
tumor cell, the BM status was regarded as DTC positive. Slides with uninterpretable cells (see 
Fig. 1.2) were regarded as DTC positive because the presence of these cells predicts clinical 
outcomes in breast cancer (235). Samples were regarded as inconclusive if they contained 
immunostained cells that were classified as tumor cells in both the AE1/AE3 slides and in the 
corresponding negative control slides. These patients were excluded from further analysis. 
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2.3.11 Statistical considerations 
General statistical methods 
Statistical calculations were mainly performed using different versions of the Statistical 
Package for Social Science (SPSS, Chicago, IL). Continuous variables with skewed 
distributions were compared using the nonparametric Mann–Whitney test or Spearman’s rho 
for correlation analysis. Categorical variables were compared using χ2 tests. Survival was 
estimated by the Kaplan–Meier method, and differences between curves were compared by 
the univariate log-rank test. Multivariate analysis of survival data was performed using Cox 
regression. The observation time ranged from the start of treatment to the date of the endpoint, 
the patient’s death, emigration, or the date of the last available clinical information, whichever 
occurred first. HRQoL scores were treated as continuous variables if a domain comprised at 
least two items. Single-item domains were treated as categorical variables in the statistical 
analysis. The internal consistency of the HRQoL scales was examined with Cronbach’s 
coefficient α. The level of statistical significance was defined as p < 0.05, and all tests were 
two sided. 
 
Statistical versus clinical significance 
Statistically significant differences within HRQoL domains on a group level may or may not 
be of clinical relevance for the patients. Two established definitions of clinical significance 
were applied in the thesis. In paper I, a difference of at least 10 points on the 0–100 scale in 
the QLQ-C30 was regarded as clinically relevant (258). In paper II, differences in HRQoL 
scores were considered clinically significant if the Cohen’s effect size was  0.40 (259;260).  
 
2.3.12 Ethical considerations 
All parts of the thesis were approved by the Regional Committee for Medical Ethics, the 
protocol review committee of the NRH, and the Norwegian Data Inspectorate. Written 
informed consent was obtained from all patients before BM sampling (papers III and IV) and 
in relation to the HRQoL surveys (papers I and II).   
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2.4 Summary of papers and main results  
2.4.1 Paper I 
The aims of this study were to evaluate long-term overall survival, cancer-specific survival, 
clinical progression-free survival, and HRQoL following definitive radiotherapy as 
monotherapy given to 203 consecutive T1–4 pN0M0 PCa patients at the NRH during 1989–
1996. In this period, radiotherapy was considered in patients with pN0M0 disease who were 
not suitable for radical prostatectomy because of extracapsular growth or patient-related 
factors such as obesity or other comorbidities. The patients were between 48 and 81 years 
(median, 66 years) when they started radiotherapy. The target dose was 66 Gy in 196 patients 
(97%), and none received neoadjuvant, concomitant or adjuvant HT. Eighty-one percent 
belonged to a high-risk group defined as cT3–4 or GS  7B. Among the 90 survivors, the 
response rate to a survey of self-reported HRQoL was 71% (n = 64). The survey occurred 10–
16 years after radiotherapy (median, 11 years), and the responders’ ages were 63–87 years 
(median, 78 years) at that time. Thirty-one of the responders (48%) had progressed clinically 
and/or used HT because of PSA recurrence at the time of the survey. The others were 
regarded as clinically free of progression when the HRQoL data were analyzed.  
 
Clinical outcomes  
All 203 patients were followed for at least 10 years except for two patients who were lost to 
follow-up after one and five years because of emigration. The 10-year probabilities of overall 
survival, cancer-specific survival, and clinical progression-free survival were 57%, 72% and 
45% respectively (Fig. 1A, paper I). The overall death rate remained relatively constant for 15 
years after therapy, whereas the risk of clinical progression tended to decline after 10 years. 
Compared with high-risk patients, low-risk patients (cT1–2 and GS  7A) had significantly 
better overall survival (79% versus 52% at 10 years), cancer-specific survival (95% versus 
66% at 10 years), and clinical progression-free survival (73% versus 39% at ten years) (Fig. 2, 
paper I). Increasing GS ( 7A versus  7B) and cT category (cT1–2 versus cT3–4) were 
independently associated with decreasing cancer-specific survival and clinical progression-
free survival (Table 2, paper I). The GS was the only independent predictor of overall 
survival. The pretreatment PSA concentration was not associated with any of the endpoints 
(Fig. 1D, paper I). Compared with age-matched controls from the general population, high-
risk patients had significantly poorer overall survival; the 10-year rates were 48% and 74%, 
respectively (p < 0.00005) (Fig. 3, paper I). Overall survival did not differ significantly 
between controls and patients with low-risk tumors. 
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Sexual function 
Eighty-seven percent of respondents had not experienced firm enough erections for sexual 
intercourse during the previous four weeks, and 63% had felt no sexual drive. The mean BSFI 
scores in patients who had progressed clinically and/or were on HT at the time of response 
were all lower than in those who were clinically free of progression (Fig. 4A, paper I). 
Compared with the normative data (171), the mean patient scores were lower within the 
sexual function domains of the BSFI and in overall sexual satisfaction (Fig. 4A, paper I). The 
scores for the clinically progression-free patients were similar to the normative data in the 
sexual problem domain.      
 
Urinary and bowel function 
Twenty-three percent of the patients had urinary leakage at least every week and 16% every 
day (Table 3, paper I). Twenty-five percent of patients used pads on a daily basis because of 
urinary leakage. Forty-four percent (n = 27) reported some degree of fecal leakage over the 
previous four weeks. Twenty of these (74%) had had involuntary leakage of feces less than 
once a week, seven about once a week, and none every day. Fifteen percent of all patients 
used pads because of fecal leakage on a daily basis. 
Nineteen percent of responders without clinical progression or HT and 14% of patients 
with clinical progression or HT regarded their urinary function to be a moderate or big 
problem. In both groups, 19% regarded their bowel habits to be a moderate or big problem. 
Compared with older American men from the general population, patients had poorer 
urinary function, more urinary bother, and more bowel bother but similar bowel function (Fig. 
4B, paper I). Compared with Norwegian normative data, patients reported clinically 
significantly more diarrhea when completing the QLQ-C30 (Table 4, paper I).   
 
General HRQoL (QLQ-C30)  
Multivariate analysis showed that better physical function and less pain were independently 
associated with better global HRQoL in the responders. Organ-specific outcomes, including 
the sexual function domains, did not independently impact on global HRQoL. 
Fifty-five of the 64 responders had been included in a similar cross-sectional survey 
about two years after radiotherapy (172). At that time, 54 had no evidence of clinical 
progression. In this subpopulation, the answers from both surveys were compared with each 
other in a longitudinal fashion. In the second survey, the mean outcomes were worse for most 
domains (Fig. 5A, paper I). The differences between mean scores tended to be greater in 
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patients who had progressed clinically and/or were on HT at the time of the second survey 
compared with progression-free patients. These findings corresponded to larger reduction in 
global HRQoL and function domains and more aggravation of symptoms in those who had 
progressed and/or used HT compared with those who remained free of progression (Fig. 5B, 
paper I). 
Compared with Norwegian normative data, patients had similar scores on global 
HRQoL (Table 4, paper I). The patient-scores for the QLQ-C30 domains of physical, role, 
emotional, and cognitive function were also scored similar to the normative data. Social 
function was also similar in the general population and patients without clinical progression, 
but patients who had progressed clinically and/or used HT had clinically poorer social 
function (difference in mean score > 10). The scores for the nine symptom domains of the 
QLQ-C30 were similar in patients and normative data except that patients had more diarrheas, 
and those who had progressed clinically and/or used HT had more insomnia. 
 
2.4.2 Paper II 
The aim was to assess self-reported HRQoL in PCa patients who had used a nonsteroidal AA 
continuously for five years as adjuvant treatment to definitive radiotherapy within the 
framework of a randomized trial (105) and compare the results to HRQoL among cancer-free, 
age-matched controls from the general population. Longitudinal changes in serum 
concentrations of sex hormones and correlations between sex hormone concentrations and 
HRQoL were also explored. 
The SPCG-7 was designed to compare AA monotherapy with AA + definitive 
radiotherapy for locally advanced or localized aggressive PCa (261). Patients were included 
from several institutions during 1996–2002. In our side study, only patients who were 
randomized to AA + radiotherapy at the NRH were included. As part of a scheduled five-year 
follow-up at the NRH, patients were invited to complete a questionnaire if they still used AA 
as their only anticancer medication and were judged to be free from distant metastases. The 
questionnaire differed from that used in the SPCG-7. Eighty-six of the 89 eligible patients 
responded (response rate of 97%). The median age at the time of the survey was 71 years 
(range, 56–79 years). Data for age-matched control cohorts were retrieved as described in the 
methodology section. 
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General HRQoL (SF-36) 
Compared with the controls, patients scored lower on the SF-36 domains of physical 
functioning, general health, and vitality (Table 3, paper II). In contrast, patients had better 
outcomes in role limitations due to emotional aspects and mental health. The SF-36 physical 
component summary score was higher in controls than in patients, whereas the mental 
component summary score was higher in patients than in controls. Although these differences 
were statistically significant, they were not clinically significant according to the calculated 
effect sizes, which were < 0.4 for all domains.   
 
Anxiety, depression and fatigue (HADS, FQ) 
HADS caseness of anxiety was found in 17% of patients and in 18% of controls (p = 0.84) 
(Table 3, paper II).  Caseness of depression was found in 17% of patients and 11% of controls 
(p = 0.37). Sixteen percent of patients and 12% of controls had chronic fatigue (p = 0.38). The 
domain scores of depression and anxiety, and mental, physical, and total fatigue were similar 
in patients and controls.    
 
Sexual function (BSFI) 
According to the predefined definitions, 64% of the patients were sexually dissatisfied 
compared with 19% of controls (p < 0.001; effect size, 0.95) (Table 3, paper II). Seventy-eight 
percent of patients and 16% of controls had erectile dysfunction (p<0.001; effect size, 1.34), 
and 55% of patients and 8% of controls lacked sexual drive (p<0.001; effect size, 1.10). All 
sexual domain scores were both statistically (p < 0.05) and clinically (effect size  0.4) lower 
in patients compared with controls.  
 
Hormonal changes  
The concentrations of testosterone, estimated free testosterone, estradiol, SHBG, FSH, and 
LH all increased significantly during the five years of AA treatment (Table 4 and Fig. 1, paper 
II). No significant correlations were found between any of the HRQoL domains and the 
concentrations of estimated free testosterone, estradiol, FSH, or LH at the time of the survey.
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2.4.3 Paper III 
The purpose of this study was to explore whether DTC-status in the BM of patients without 
overt metastases is associated with clinical or histopathological factors at diagnosis or with 
clinical outcome subsequent to definitive radiotherapy. During 1994–2004, conclusive BM 
aspirates were sampled from 266 patients referred to the Department of Oncology, NRH 
because of newly diagnosed cT1–4pN0M0 PCa. The relationship between DTC status and other 
factors at diagnosis was studied in all patients. The prognostic impact of having DTCs in the 
BM at diagnosis was studied among patients who had completed definitive radiotherapy and 
had at least one poor prognostic factor at diagnosis (defined as cT3–4, PSA  10 μg/L or GS  
7B) and who started treatment at least five years before the study’s cutoff date (n = 131).   
 
Prevalence of DTCs prior to treatment 
Eighteen percent of all 266 patients (n = 48) had positive DTC status before treatment. The 
number of DTCs per 2´106 mononuclear cells were 11 in one patient, four in two patients, 
three in six patients, two in nine patients and one in 30 patients. Positive DTC status was 
significantly associated with increasing GS (p = 0.04, Fig. 1, paper III) and increasing 
percentage of G4/5 (p = 0.04). DTC status was not associated with cT category, PSA 
concentration, or dichotomized GS ( 7A versus  7B) (Table II, paper III). 
 
Prognostic impact of DTCs in the BM before treatment 
With a median follow-up of seven years, the presence of DTCs at diagnosis tended to predict 
the development of distant metastases as the first clinical relapse (p = 0.07) but was not 
associated with any other endpoints of failure (Table III, paper III). The seven-year risks of 
distant metastases as first clinical relapse were 21% for DTC-positive patients versus 6% for 
DTC-negative patients (Fig. 2A, paper III). Clinical outcome did not differ between patients 
with one DTC per 2´106 mononuclear cells and those with more than one DTC per 2´106 
mononuclear cells. Among patients with a GS  7B, positive DTC status was significantly 
associated with greater risk of distant metastases as the first clinical relapse (p = 0.04); the 
seven-year probabilities of DTC-positive and DTC-negative patients were 34% and 10%, 
respectively (Fig. 2B, paper III). DTC status was not associated with the development of 
distant metastases in patients with GS  7A (Fig. 2B, paper III). Seventy-five of the patients 
in the follow-up cohort had received radiotherapy as monotherapy. Among these, the risk for 
distant metastases as the first clinical relapse was also significantly higher for DTC-positive 
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patients than for DTC-negative patients; the seven-year probabilities were 28% and 9%, 
respectively (p = 0.03) (Fig. 3, paper III).  
 
2.4.4 Paper IV  
The purpose was to explore the prevalence of DTCs in the BM of clinically progression-free 
PCa patients two or more years after definitive radiotherapy with or without HT. Conclusive 
BM samples were obtained from 130 clinically progression-free patients following 
radiotherapy monotherapy (treatment group 1, n = 56); radiotherapy + neoadjuvant, 
concomitant, and adjuvant medical castration for a total of two or three years (treatment group 
2, n = 27); or radiotherapy + continuous nonsteroidal AA (treatment group 3, n = 47). The 
median time from the start of treatment to BM sampling was five years (range, 2–8 years). All 
patients in treatment group 2 had been without HT for at least one year before BM aspiration, 
and all in treatment group 3 still used AA. At the time of BM sampling, 20 patients (15%) had 
developed PSA recurrence.  The longitudinal changes in DTC status were studied in a sub-
group of 109 patients who had donated BM before treatment. 
 
Prevalence of DTCs in BM following radiotherapy  
Overall, 22 patients (17%) had DTCs in their post-radiotherapy BM. The numbers of DTCs 
per 2´106 mononuclear cells were one in 15 patients, two in four patients, three in one patient, 
four in one patient and 11 in one patient. The posttreatment DTC status was not associated 
with pretreatment PSA concentration, cT category, GS, risk stratification, or treatment group 
(Table II, paper IV). The posttreatment DTC status was not associated with the concentrations 
of PSA or testosterone at the time of aspiration (Tables III and IV, paper IV). 
 
Longitudinal changes in BM status  
Of the 14 patients who had a positive DTC status before treatment, only one (7%) remained 
positive in the posttreatment sample. Eighteen (19%) of the 95 patients who were DTC 
negative before treatment were DTC positive after treatment, and the posttreatment DTC 
status did not differ between treatment groups (Table V, paper IV).  
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2.5 General discussion 
2.5.1 Methodological considerations 
Clinical endpoints in survival analyses (papers I and III) 
The endpoint overall survival was based on reliable data from the Central Population 
Registry. Death in a patient because of PCa was determined retrospectively based on the 
available medical records. The same was done for the endpoints clinical progression-free 
survival in paper I and distant metastases as the first clinical relapse, local failure as first 
clinical relapse, and biochemical failure in paper III. The accuracy of these endpoints was 
influenced to some degree by the intensity of diagnostic procedures during follow-up, which 
was not predefined. Both local failures and distant metastases may have been underreported in 
patients for whom HT had been prescribed because of increasing PSA without a prior digital 
rectal examination or imaging. However, we believe that most cases with symptomatic distant 
metastases were identified. Because the patients were followed by many different clinicians, 
we do not suspect a systematic underreporting of clinical events. In addition, the endpoints 
were determined before matching with DTC status in paper III. Nevertheless, we cannot 
exclude the possibility of biased distributions of underreported clinical events in the different 
groups. The results in paper III should be reproduced in studies that base the scoring of 
clinical endpoints on prospective follow-up protocols. 
 
HRQoL assessment (papers I and II) 
Cross-sectional studies of HRQoL following treatment can provide only associations. In 
particular, strong conclusions about treatment-induced side effects cannot be drawn because 
baseline data are missing. In addition, self-reported outcomes may be confounded by factors 
such as age, disease progression, and comorbidity. The optimal study should comprise both 
baseline data and a randomized untreated control group. No such study of the radical 
treatment of PCa has been published. Comparison with cross-sectional data from normative 
samples, as done in papers I and II, is another approach to provide insight into cancer-related 
morbidity. The validity of such comparison depends on whether each sample is representative 
for the population of interest. In paper I, the mean patient scores were compared directly with 
published mean scores from the general Norwegian and American populations. Because of 
possible cross-cultural differences in self-reported outcomes (262), a substantial risk of 
unrecognized bias, and small sample size in the patient groups, the validity of such 
comparison may be questioned. We chose to present the mean scores without performing 
statistical analysis. In paper II, we retrieved data for age-matched control cohorts from a 
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sample of cancer-free Norwegian men that were similar to the patients regarding level of 
education and paired relations, which gave smaller risk of sampling bias than that in paper I. 
However, this may have occurred because of the low response rate of the controls (~35%). A 
higher response rate is difficult to achieve in population-based surveys on sexual function 
(169). The response rate of 97% among patients was very satisfactory. However, the study did 
not include those who had stopped AA treatment before the five-year follow-up, and this may 
have resulted in a selection bias, i.e. selection of patients who had not experienced 
unacceptable side effects from AAs. 
 
Detection of DTCs (papers III and VI)   
The sensitivity of assays for DTC detection depends on a number of methodological factors. 
In the applied standardized method, 2´106 mononuclear cells were analyzed for DTCs 
following enrichment by density centrifugation. Even though the sensitivity increased when a 
more mononuclear cells from breast cancer patients were examined, the predictive impact of 
early systemic relapse was reduced (263). The explanation may be that a certain load of DTCs 
is necessary for the development of distant metastases. An increased sensitivity may therefore 
not be beneficial from a clinical point of view if it hampers the positive predictive value of a 
test. Nevertheless, increased sensitivity may also be achieved by immunomagnetic separation 
techniques (74). Such methods may be feasible for isolating a sufficient number of cells for 
biological characterization but may reduce the specificity and positive predictive value. The 
sensitivity may be affected by the amount of peripheral blood contamination (201), whether or 
not DTCs are trapped in the granulocyte compartment following density centrifugation (264), 
and the anticytokeratin antibody (201).  
The specificity of DTC detection must also be considered. False-positive 
immunostaining of hematopoietic cells can occur (232), and we performed control staining 
with an irrelevant antibody in addition to careful morphological evaluation of all stained cells 
(177). Despite these procedures, cells that were evaluated as DTCs have been found in the 
BM from 4% of female donors without known epithelial cancers (236). It is unknown whether 
these cells originate from unknown cancers or represent false-positive-stained benign cells 
that imitate tumor cells. We did not include a control group of men without PCa. This would 
be difficult to achieve, given the high frequency of undetected prostate tumors, even in men 
with PSA concentrations < 3.0μg/L (see Table 1.2) (265). Therefore, we do not know the 
exact false positive-rate for the assay applied on men with PCa, but do not expect that it 
differs significantly from the 4% in women.  
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Because the BM studies included patients over a 10 year time-period, the 
methodological development caused some variation in the BM sample processing. As 
accounted for in paper III, only one negative control slide was stained for each test before 
1999 versus four control slides thereafter (232). We cannot exclude the possibility that some 
DTC-positive patients would have been excluded because of positive scoring both in the 
specific test and in the negative control if four control slides had been investigated at the 
earlier times. Furthermore, the manual screening for immunostained slides is vulnerable to 
intra- and interobserver variability, which may be reduced by automatic screening (233). All 
slides in paper III and slides from the pre- radiotherapy samples in paper IV were screened 
manually and most of the post-radiotherapy slides in paper IV were screened automatically.  
We do not suspect that any of the factors discussed led to systematically skewed 
distributions of BM-positive patients within the groups.  
 
2.5.2 Discussion of specific results 
Paper I 
It is clear that most of the patients in paper I received a suboptimal treatment according to 
current standards. First, radiotherapy doses < 74Gy would now be considered by most 
radiotherapists to be insufficient to achieve local control (128), even though the optimal 
radiotherapy dose for different patients remains to be settled (129). Most of the studied 
patients would today have received adjuvant HT because of poor prognostic factors such as 
PSA concentration > 10μg/L, GS  7, or extracapsular tumor extension (94-98;104). 
Nevertheless, long-term follow-up studies such as ours with clinically robust endpoints such 
as cancer-specific survival and overall survival serve as important historical references for 
evaluating newer regimes. The use of overall and PCa-specific mortality is especially 
important when studying PCa because many clinical studies use PSA recurrence as a final 
endpoint because of the long follow-up time needed to observe clinical events. In addition, 
only a few published series have evaluated definitive radiotherapy in surgically staged pN0 
patients (228;229;266). Together with the 10-year probabilities of 66% for cancer-specific 
survival and 39% for clinical progression-free survival in our study, the higher death rate in 
high-risk patients than in age-matched controls from the general population confirms the need 
for more effective treatment strategies such as dose escalation
 
and/or adjuvant HT for patients 
with a GS  7B or cT3–4. Patients with GS  7A and T1–2 had similar overall survival rate as 
did the controls (Fig. 3, paper I). This finding, together with a 10-year cancer-specific survival 
of 95%, may support active surveillance of selected low-risk patients (112). On the other 
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hand, the 10-year probability of clinically progression-free survival was 79% in these patients, 
demonstrating that some of these tumors are clinically relevant. One should bear in mind that 
our definition of low risk in paper I does not correspond to contemporary definitions of 
indolent disease in a screening setting (267) because our patients had all clinically detectable 
or symptomatic tumors.  
In our study, of the three traditional prognostic factors  the GS, cT category, and 
pretreatment PSA  only the GS and cT category were significant predictors of the clinical 
endpoints. Our results agree with the patterns of care study from 1989, in which pretreatment 
PSA concentration was an independent risk factor for PSA recurrence but not for clinical 
failure or death when the GS was included in multivariate analysis (268). 
The patients did not receive radiation of the pelvic lymph nodes because of their 
histopathologically verified pN0 status. Only a median of eight lymph nodes were removed 
even though clinical and anatomical studies indicate that extended dissection to remove at 
least 20 pelvic lymph nodes is required for optimal staging (22;23;269). A certain degree of 
understaging is suspected, which may have affected the results. Both limited lymph node 
dissection and widely used nomograms (21;140) probably underestimate the risk of lymph 
node involvement (26;56;269). These uncertainties about the correct N classification in PCa 
patients hamper development of adjuvant treatment regimes based on correct staging similar 
to what has been achieved in breast cancer over the past decades (270). 
The poor sexual function compared with the normative data was expected based on 
longitudinal studies that showed a gradual decline in sexual function the first five years after 
radiotherapy (164;271). In addition, 44% were on HT at the time of the survey. It is 
interesting that the sexual problem scores in patients and the general population are similar 
despite the large difference in sexual function. It seems that the PCa survivors have a different 
perception of sexual problems than the controls. As discussed in the paper, this may be 
explained by a response shift among cancer survivors (174). 
  Twenty-five percent of the respondents used pads because of urinary leakage on a 
daily basis. In the study by Korfage et al, urinary function was also assessed by the PCI and 
only 6% used urinary pads at the five year follow-up (164). This discrepancy may indicate 
late radiation toxicity that leads to increasing urinary leakage after five years but may also 
reflect the fact that our patients were older, with more urinary comorbidity. Results from a 
small longitudinal study by Fransson support the first explanation. Urinary incontinence was 
similar at the four-year and eight-year follow-ups, but had increased markedly at the 15-year 
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follow-up without a corresponding increase in urinary incontinence in age-matched controls 
(157).     
In paper I, we questioned the ability of the PCI bowel function scale to measure 
radiotherapy-induced bowel dysfunction because the patients’ scores were similar to those 
from the normative sample. This may also be explained by a gradual decrease in late-onset 
bowel symptoms following radiotherapy (146). In contrast to our results, in the longitudinal 
study by Korfage et al, bowel function was reduced by about 10 points on the 0–100 scale 
from baseline to six months after radiotherapy and remained at that level on the next 
measurements (164).  
The patients’ global HRQoL scores 10–16 years after radiotherapy corresponded well 
with scores from the general population, indicating that radiotherapy has little direct effect on 
this domain. Although longitudinal studies have shown some inconsistent results regarding 
changes in general HRQoL domains in the first year after radiotherapy, they generally 
indicate that the changes, if any, are relatively small (164;272;273). Our results support others 
who have pointed out that organ-related morbidity may have relatively little effect on self-
reported global HRQoL in PCa survivors (164;274). On the other hand, poor urinary function, 
urinary bother, sexual function, and sexual bother were independently associated with worse 
generic HRQoL outcomes assessed by SF-36 two years after diagnosis of PCa in a large 
American population-based study (173).  
 The longitudinal reduction in the global HRQoL and general function domains 
observed in our patients compared with a similar survey two years after radiotherapy was 
most likely confounded by age (170) and disease progression (Fig. 5, paper I) but was 
probably not a specific result of late toxicity from radiotherapy.  
 
Paper II 
As discussed in the paper, preserved sexual-function has been thought to be an advantage of 
AAs compared with castration based therapy (102). However, the evidence has been based on 
short-term studies with substantial risk of under-reporting of sexual dysfunction (275-277). 
The patients studied in paper II received long-term AA + radiotherapy. The poor sexual 
function that they reported compared with the general population may have been confounded 
by radiotoxicity (153). However, a severe reduction in sexual function associated with long-
term AA monotherapy has recently been reported (105). A previous study reported a gradual 
decrease in erectile function the first 2–6 years of flutamide (103). Together with our results, 
these studies indicate that long-term AA may reduce sexual function in most patients. A 
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gradual decrease in sexual function remains an advantage compared with the sudden decrease 
that often occurs during medical castration.   
We expected that the patients would score lower than the controls on the HRQoL 
domains depression, vitality, physical functioning, and physical fatigue because these 
domains are believed to be partly dependent on androgen-receptor activity. However, the 
differences between patients and controls in these domains were small and not necessarily 
clinically important. Except for the possibility of type II errors because of small sample sizes, 
one reason may be that AAs do not have significantly affect these domains. An alternative 
explanation is that the patients had better baseline scores compared with the controls because 
major comorbidities would have excluded them from definitive radiotherapy. If so, we would 
not have expected the statistically significantly better general health in controls compared 
with patients.  
 The increase in sex hormone concentrations during AA treatment is well known 
(99;231), but earlier reports had shorter follow-up compared with the five years in our study. 
As noted in the paper, the consequences of increased sex hormone concentrations are not 
known. Medical castration achieved by estrogens is associated with cardiovascular toxicity 
(93). Theoretically, this may also apply to patients with increased serum estradiol 
concentration because of AA treatment. Although the results provide strong evidence of an 
increase in sex hormone concentration on a group level, this did not occur in all patients, and 
some patients had lower concentrations at the follow-up compared with baseline. Possible 
causes for these different responses are poor patient compliance or pharmacogenetic 
differences between patients.      
        
Paper III 
Before this study, Weckermann et al had shown that pretreatment DTCs in the BM detected 
by ICC predicted PSA-based progression following radical prostatectomy (76). Our study is 
the first to show that pretreatment DTC status in BM predicts development of distant 
metastases after radical treatment for PCa. The hypothesis that these cells are precursors of 
distant metastases has been strengthened by a recent study showing that pretreatment DTC 
status predicts PSA recurrence following radical prostatectomy with neoadjuvant HT (72). 
However, the clinical relevance of detecting these cells in PCa patients is far from settled. 
PSA recurrence is only a surrogate endpoint for clinical relapse. The endpoint of distant 
metastases in our study was assessed retrospectively. The clinical relevance of detecting 
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DTCs in the BM of PCa patients before treatment needs to be confirmed in prospective trials 
with clinically robust endpoints before the findings can be implemented in clinical practice.   
 The prevalence of pretreatment DTCs was 40% and 45% in the studies by 
Weckermann et al and Kollermann et al compared with only 18% in our study even though 
the same number of mononuclear cells was examined (2´106). Using an enrichment method 
that included both negative and positive immunomagnetic selection and the epithelial marker 
BerEp4, Pfitzenmeyer et al found BM epithelial cells in as many as 75% of PCa patients 
before prostatectomy (74). The variability between studies may be related to several factors 
such as the use of different antibodies and differences in the morphological evaluation of 
immunostained cells (177). The low prevalence in our study may reflect the effort to select 
patients without regional lymph node metastases by surgical staging and central reviewing of 
all histopathological specimens.  
In contrast to the three studies discussed above, we found that the risk of having DTCs 
in the BM before treatment increased with an increasing GS. In our study, all biopsies were 
graded by one pathologist to avoid interobserver variation. The high prevalence of DTCs in 
the other studies suggests that their methods had less specificity than ours. From a biological 
point of view, a connection between an increasing GS and DTC status could partly explain 
why the GS is such a strong predictor of the progression of PCa (68). Because the presence of 
DTCs in breast cancer is associated with histopathological grade (188), the same would be 
expected in PCa.  
  
Paper IV 
In this study, the similar prevalence of positive DTC status following radiotherapy with or 
without adjuvant HT indicates that HT does not kill DTCs. This agrees with results showing 
that pretreatment DTC status is a predictor of clinical progression despite neoadjuvant HT for 
PCa (72) and adjuvant HT for breast cancer (188). The inconsistent BM findings at follow-up 
compared with baseline may reflect a true biological phenomenon but may also be related to 
the relatively low sensitivity of the method applied as mentioned previously.  
 
 
 
 
 
 62
2.6 Conclusions related to the study aims 
1. Among patients who received definitive radiotherapy  70Gy monotherapy at the NRH 
between 1989 and 1996, the 10-year overall survival, cancer-specific survival, and clinical 
progression-free survival were 57%, 72%, and 45%, respectively. GS  7B and cT3–4 were 
independently associated with decreased cancer-specific survival and clinical progression-free 
survival whereas a GS  7B was the only independent predictor of decreased overall survival. 
Patients with GS  7B or cT3–4 had reduced overall survival compared with age-matched 
controls from the general population. In contrast, patients with GS  7A and cT1–2 had a 
similar overall survival as controls. 
 
2. Between 10 and 16 years after definitive radiotherapy for PCa, 89% of responders had 
complete erectile dysfunction, 23% had urinary leakage at least once every week, and 11% 
had fecal leakage at least once a week. Compared with published normative data, the patients 
had similar global HRQoL. Pelvic-specific morbidities probably related to radiotherapy were 
not independently associated with global HRQoL.  
 
3. Compared with age-matched controls from the general population, patients who had been 
treated by definitive radiotherapy + long-term adjuvant nonsteroidal AA reported markedly 
decreased sexual function combined with limitations of physical functioning, general health, 
and vitality. 
 
4. Serum concentrations of testosterone, estimated free testosterone, estradiol, SHBG, LH, 
and FSH increased significantly in patients who had used AA for five years.   
 
5. DTCs were found in the BM of 18% of patients with cT1–4pN0M0 PCa before therapy. The 
prevalence of positive DTC status increased with increasing GS and increasing percentage of 
Gleason grade 4 or 5.   
 
6. The appearance of DTCs in the BM seems to predict the development of distant metastases 
after curatively intended radiotherapy for high-grade PCa.  
 
7. The prevalence of a positive DTC status was 17% following definitive radiotherapy for 
PCa and was independent of whether the patients had received radiotherapy as monotherapy, 
adjuvant castration-based HT, or adjuvant AA.   
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2.7 Future considerations 
The current thesis and related studies warrant further clinical investigations to address the 
following: 
 
1. The optimal radiotherapy dose and adjuvant treatment may differ according to cancer-
related and patient-related factors. Both should be included in future randomized trials. 
 
2. The search for better prognostic markers must continue so that treatment can be 
differentiated according to biological properties of the specific tumor. New prognostic 
markers should be evaluated by clinical survival endpoints in long-term studies, and not only 
by PSA.  
 
3. Side-effects from long-term AA treatment should be evaluated further. Possible 
cardiovascular consequences from increased serum estradiol concentration in response to AA 
treatment should be addressed specifically.  
 
4. HRQoL following contemporary curative treatment strategies for PCa should be assessed 
continuously in long-term longitudinal studies that include baseline data and representative 
control groups. 
 
6. If pre-radiotherapy lymph node staging is continued in future clinical practice, the method 
should be standardized.  
  
7. The clinical implications of detecting DTCs in the BM of PCa patients remain to be 
evaluated in large, prospective trials. The prognostic impact of detecting DTCs by different 
methods such as direct ICC, ICC following immunomagnetic separation, and quantitative RT-
PCR should be compared. No studies have evaluated the prognostic value of detecting DTCs 
following radiotherapy combined with HT. Future studies should also focus on 
methodological standardization and biological characterization of the cells. Ultimately, 
specific therapeutic targets may be identified on the DTCs that could guide adjuvant treatment 
in the individual patient.  
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